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Summary
This report updates the 2006 recommendations by CDC’s Advisory Committee on Immunization Practices (ACIP) regarding the
use of influenza vaccine and antiviral agents (CDC. Prevention and control of influenza: recommendations of the Advisory
Committee on Immunization Practices [ACIP]. MMWR 2006;55[No. RR-10]). The groups of persons for whom vaccination
is recommended and the antiviral medications recommended for chemoprophylaxis or treatment (oseltamivir or zanamivir) have not
changed. Estimated vaccination coverage remains <50% among certain groups for whom routine annual vaccination is recom-
mended, including young children and adults with risk factors for influenza complications, health-care personnel (HCP), and
pregnant women. Strategies to improve vaccination coverage, including use of reminder/recall systems and standing orders programs,
should be implemented or expanded. The 2007 recommendations include new and updated information. Principal updates and
changes include 1) reemphasizing the importance of administering 2 doses of vaccine to all children aged 6 months–8 years if they
have not been vaccinated previously at any time with either live, attenuated influenza vaccine (doses separated by >6 weeks) or
trivalent inactivated influenza vaccine (doses separated by >4 weeks), with single annual doses in subsequent years; 2) recommend-
ing that children aged 6 months–8 years who received only 1 dose in their first year of vaccination receive 2 doses the following year,
with single annual doses in subsequent years; 3) highlighting a previous recommendation that all persons, including school-aged
children, who want to reduce the risk of becoming ill with influenza or of transmitting influenza to others should be vaccinated;
4) emphasizing that immunization providers should offer influenza vaccine and schedule immunization clinics throughout the
influenza season; 5) recommending that health-care facilities consider the level of vaccination coverage among HCP to be one measure
of a patient safety quality program and implement policies to encourage HCP vaccination (e.g., obtaining signed statements from
HCP who decline influenza vaccination); and 6) using the 2007–2008 trivalent vaccine virus strains A/Solomon Islands/3/2006
(H1N1)-like (new for this season), A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. This report and
other information are available at CDC’s influenza website (http://www.cdc.gov/flu). Updates or supplements to these recommendations
(e.g., expanded age or risk group indications for currently licensed vaccines) might be required. Immunization providers should be alert
to announcements of recommendation updates and should check the CDC influenza website periodically for additional information.
Introduction
In the United States, annual epidemics of influenza occur
typically during the late fall and winter seasons; an annual
average of approximately 36,000 deaths during 1990–1999
and 226,000 hospitalizations during 1979–2001 have been
associated with influenza epidemics (1,2). Influenza viruses
can cause disease among persons in any age group (3–5), but
rates of infection are highest among children. Rates of serious
illness and death are highest among persons aged >65 years,
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children aged <2 years, and persons of any age who have medical
conditions that place them at increased risk for complications
from influenza (3,6–8).
Influenza vaccination is the most effective method for pre-
venting influenza virus infection and its potentially severe com-
plications. Influenza immunization efforts are focused
primarily on providing vaccination to persons at risk for
influenza complications and to contacts of these persons (Box).
Influenza vaccine may be administered to any person aged
>6 months to reduce the likelihood of becoming ill with
influenza or of transmitting influenza to others; if vaccine sup-
ply is limited, priority for vaccination is typically assigned to
persons in specific groups and of specific ages who are, or are
contacts of, persons at higher risk for influenza complications.
Trivalent inactivated influenza vaccine (TIV) may be used for
any person aged >6 months, including those with high-risk
conditions. Live, attenuated influenza vaccine (LAIV) cur-
rently is approved only for use among healthy, nonpregnant
persons aged 5–49 years. Because influenza viruses undergo
frequent antigenic change (i.e., antigenic drift), persons rec-
ommended for vaccination must receive an annual vaccina-
tion against the influenza viruses currently in circulation.
Although vaccination coverage has increased in recent years for
many groups recommended for routine vaccination, coverage
remains unacceptably low, and strategies to improve vaccina-
tion coverage, including use of reminder/recall systems and
standing orders programs, should be implemented or expanded.
Antiviral medications are an adjunct to vaccination and are
effective when administered as treatment and when used for
chemoprophylaxis after an exposure to influenza virus.
Oseltamivir and zanamivir are the only antiviral medications
currently recommended for use in the United States. Resis-
tance to oseltamivir or zanamivir remains rare. Amantadine
or rimantidine should not be used for the treatment or pre-
vention of influenza in the United States until evidence of
susceptibility to these antiviral medications has been reestab-
lished among circulating influenza A viruses.
Methods
CDC’s Advisory Committee on Immunization Practices
(ACIP) provides annual recommendations for the prevention
and control of influenza. The ACIP Influenza Vaccine Work-
ing Group* meets monthly throughout the year to discuss
newly published studies, review current guidelines, and con-
sider potential revisions to the recommendations. As they
review the annual recommendations for ACIP consideration,
members of the Working Group consider a variety of issues,
including vaccine effectiveness, safety and coverage in groups
recommended for vaccination, feasibility, cost-effectiveness,
and anticipated vaccine supply. Working Group members also
request periodic updates on vaccine and antiviral production,
supply, safety and efficacy from vaccinologists, epidemiolo-
gists and manufacturers. State and local immunization pro-
gram representatives are consulted. Influenza surveillance and
antiviral resistance data were obtained from CDC’s Influenza
Division. The Vaccines and Related Biological Products
Advisory Committee of the Food and Drug Administration
(FDA) selects the viral strains to be used in the annual triva-
lent influenza vaccines.
BOX. Persons for whom annual vaccination is recommended
Annual vaccination against influenza is recommended for
• all persons, including school-aged children, who want
to reduce the risk of becoming ill with influenza or of
transmitting influenza to others
• all children aged 6–59 months (i.e., 6 months–4 years);
• all persons aged >50 years;
• children and adolescents (aged 6 months–18 years)
receiving long-term aspirin therapy who therefore might
be at risk for experiencing Reye syndrome after influ-
enza virus infection;
• women who will be pregnant during the influenza season;
• adults and children who have chronic pulmonary
(including asthma), cardiovascular (except hyperten-
sion), renal, hepatic, hematological or metabolic disor-
ders (including diabetes mellitus);
• adults and children who have immunosuppression
(including immunosuppression caused by medications
or by human immunodeficiency virus;
• adults and children who have any condition (e.g., cogni-
tive dysfunction, spinal cord injuries, seizure disorders,
or other neuromuscular disorders) that can compromise
respiratory function or the handling of respiratory secre-
tions or that can increase the risk for aspiration;
• residents of nursing homes and other chronic-care
facilities;
• health-care personnel;
• healthy household contacts (including children) and
caregivers of children aged <5 years and adults aged >50
years, with particular emphasis on vaccinating contacts
of children aged <6 months; and
• healthy household contacts (including children) and
caregivers of persons with medical conditions that put them
at higher risk for severe complications from influenza.
* A list of members appears on the inside back cover of this report.
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Published, peer-reviewed studies identified through litera-
ture searches are the primary source of data used in making
these recommendations. Among studies discussed or cited,
those of greatest scientific quality and those that measured
influenza-specific outcomes were the most influential during
the development of these recommendations. For example,
population-based estimates that use outcomes associated with
laboratory-confirmed influenza virus infection contribute the
most specific data for estimates of influenza burden. The best
evidence for vaccine or antiviral efficacy and effectiveness stud-
ies comes from randomized controlled trials that assess labo-
ratory-confirmed influenza infections as an outcome measure
and consider factors such as timing and intensity of influenza
circulation and degree of match between vaccine strains and
wild circulating strains (9,10). Randomized, placebo-
controlled trials cannot be performed in populations for which
vaccination already is recommended, but observational stud-
ies that assess outcomes associated with laboratory-confirmed
influenza infection can provide important vaccine effective-
ness data. Randomized, placebo-controlled clinical trials are
the best source of vaccine and antiviral safety data for com-
mon adverse events; however, such studies do not have the
power to identify rare but potentially serious adverse events.
The frequency of rare adverse events that might be associated
with vaccination or antiviral treatment is best assessed by ret-
rospective reviews of computerized medical records from large
linked clinical databases, with chart review for persons who
are identified as having a potential adverse event after vacci-
nation (11,12). Vaccine coverage data from a nationally rep-
resentative, randomly selected population that includes
verification of vaccination through health-care record review
is superior to coverage data derived from limited populations
or without verification of immunization but is rarely avail-
able for older children or adults (13). Finally, studies that
assess immunization program practices that improve vaccina-
tion coverage are most influential in formulating recommen-
dations if the study design includes a nonintervention
comparison group. In cited studies that included statistical
comparisons, a difference was considered to be statistically
significant if the p-value was <0.05 or the 95% confidence
interval (CI) around an estimate of effect allowed rejection of
the null hypothesis (i.e., no effect).
These recommendations were presented to the full ACIP
and approved in February 2007. Modifications were made to
the ACIP statement during the subsequent review process at
CDC to update and clarify wording in the document. Data
presented in this report were current as of June 27, 2007.
Further updates, if needed, will be posted at CDC’s influenza
website (http://www.cdc.gov/flu).
Primary Changes and Updates
in the Recommendations
The 2007 recommendations include six principal changes
or updates:
• ACIP reemphasizes the importance of administering
2 doses of vaccine to all children aged 6 months–8 years
if they have not been vaccinated previously at any time
with either LAIV (doses separated by >6 weeks) or TIV
(doses separated by >4 weeks), on the basis of accumulat-
ing data indicating that 2 doses are required for protec-
tion in these children (see Vaccine Efficacy, Effectiveness,
and Safety).
• ACIP recommends that children aged 6 months–8 years
who received only 1 dose in their first year of vaccination
receive 2 doses the following year (see Vaccine Efficacy,
Effectiveness, and Safety).
• ACIP reiterates a previous recommendation that all
persons, including school-aged children, who want to
reduce the risk of becoming ill with influenza or of trans-
mitting influenza to others should be vaccinated (see Box
and Recommendations for Using TIV and LAIV During
the 2007–08 Influenza Season).
• ACIP emphasizes that immunization providers should
offer influenza vaccine and schedule immunization clin-
ics throughout the influenza season (see Timing of Vacci-
nation).
• ACIP recommends that health-care administrators con-
sider the level of vaccination coverage among health-
care personnel (HCP) to be one measure of a patient
safety quality program and implement policies to
encourage HCP vaccination (e.g., obtaining signed state-
ments from HCP who decline influenza vaccination)
(see Additional Information Regarding Vaccination of
Specific Populations).
• The 2007–2008 trivalent vaccine strains are
A/Solomon Islands/3/2006 (H1N1)-like (new for this
season), A/Wisconsin/67/2005 (H3N2)-like, and
B/Malaysia/2506/2004-like viruses. (see Recommenda-




Influenza A and B are the two types of influenza viruses
that cause epidemic human disease (14). Influenza A viruses
are categorized into subtypes on the basis of two surface anti-
gens: hemagglutinin and neuraminidase. Currently circulat-
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ing influenza B viruses are separated into two distinct genetic
lineages but are not categorized into subtypes. Since 1977,
influenza A (H1N1) viruses, influenza A (H3N2) viruses, and
influenza B viruses have circulated globally. In certain recent
years, influenza A (H1N2) viruses that probably emerged
after genetic reassortment between human A (H3N2) and
A (H1N1) viruses also have circulated. Both influenza A sub-
types and B viruses are further separated into groups on the
basis of antigenic similarities. New influenza virus variants
result from frequent antigenic change (i.e., antigenic drift)
resulting from point mutations that occur during viral repli-
cation. Influenza B viruses undergo antigenic drift less rap-
idly than influenza A viruses.
Immunity to the surface antigens, particularly the hemag-
glutinin, reduces the likelihood of infection (15). Antibody
against one influenza virus type or subtype confers limited or
no protection against another type or subtype of influenza
virus. Furthermore, antibody to one antigenic type or sub-
type of influenza virus might not protect against infection
with a new antigenic variant of the same type or subtype (16).
Frequent emergence of antigenic variants through antigenic
drift is the virologic basis for seasonal epidemics as well as the
reason for annually reassessing the need to change one or more
of the recommended strains for influenza vaccines.
More dramatic changes, or antigenic shifts, occur less fre-
quently and can result in the emergence of a novel influenza
A virus with the potential to cause a pandemic. Antigenic shift
occurs when a new subtype of influenza A virus emerges (14).
New influenza A subtypes have the potential to cause a pan-
demic when they are demonstrated to be able to cause human
illness and demonstrate efficient human-to-human transmis-
sion, in the setting of little or no previously existing immu-
nity among humans.
Clinical Signs and Symptoms
of Influenza
Influenza viruses are spread from person to person prima-
rily through large-particle respiratory droplet transmission
(e.g., when an infected person coughs or sneezes near a sus-
ceptible person) (14). Transmission via large-particle droplets
requires close contact between source and recipient persons,
because droplets do not remain suspended in the air and gen-
erally travel only a short distance (<1 meter) through the air.
Contact with respiratory-droplet contaminated surfaces is
another possible source of transmission. Airborne transmis-
sion (via small-particle residue [<5µm] of evaporated droplets
that might remain suspended in the air for long periods of
time) also is thought to be possible, although data supporting
airborne transmission are limited (17–20). The typical incu-
bation period for influenza is 1–4 days (average: 2 days) (21).
Adults can be infectious from the day before symptoms begin
through approximately 5 days after illness onset. Young chil-
dren also might shed virus several days before illness onset,
and children can be infectious for >10 days after onset of symp-
toms. Severely immunocompromised persons can shed virus
for weeks or months (22–25).
Uncomplicated influenza illness is characterized by the
abrupt onset of constitutional and respiratory signs and symp-
toms (e.g., fever, myalgia, headache, malaise, nonproductive
cough, sore throat, and rhinitis) (26). Among children, otitis
media, nausea, and vomiting also are commonly reported with
influenza illness (27–29). Uncomplicated influenza illness typi-
cally resolves after 3–7 days for the majority of persons,
although cough and malaise can persist for >2 weeks. How-
ever, influenza virus infections can cause primary influenza
viral pneumonia; exacerbate underlying medical conditions
(e.g., pulmonary or cardiac disease); lead to secondary bacte-
rial pneumonia, sinusitis, or otitis; or contribute to coinfections
with other viral or bacterial pathogens (30–32). Young chil-
dren with influenza virus infection might have initial symp-
toms mimicking bacterial sepsis with high fevers (31–34), and
febrile seizures have been reported in 6%–20% of children
hospitalized with influenza virus infection (28,31,35). Popu-
lation-based studies among hospitalized children with labora-
tory-confirmed influenza have demonstrated that although
the majority of hospitalizations are brief (<2 days), 4%–11%
of children hospitalized with laboratory-confirmed influenza
required treatment in the intensive care unit, and 3% required
mechanical ventilation (31,33). Among 1,308 hospitalized
children in one study, 80% were aged <5 years, and 27% were
aged <6 months (31). Influenza virus infection also has been
uncommonly associated with encephalopathy, transverse
myelitis, myositis, myocarditis, pericarditis, and Reye syn-
drome (28,30,36,37).
Respiratory illnesses caused by influenza virus infection are
difficult to distinguish from illnesses caused by other respira-
tory pathogens on the basis of signs and symptoms alone. Sen-
sitivity and predictive value of clinical definitions can vary,
depending on the degree of circulation of other respiratory
pathogens and the level of influenza activity (38). Among gen-
erally healthy older adolescents and adults living in areas with
confirmed influenza virus circulation, estimates of the posi-
tive predictive value of a simple clinical definition of influ-
enza (cough and fever) for laboratory-confirmed influenza
infection have varied (range: 79%–88%) (39,40).
Young children are less likely to report typical influenza
symptoms (e.g., fever and cough). In studies conducted among
children aged 5–12 years, the positive predictive value of
fever and cough together was 71%–83%, compared with 64%
Vol. 56 / RR-6 Recommendations and Reports 5
among children aged <5 years (41). In one large, population-
based surveillance study in which all children with fever or
symptoms of acute respiratory tract infection were tested for
influenza, 70% of hospitalized children aged <6 months with
laboratory-confirmed influenza were reported to have fever
and cough, compared with 91% of hospitalized children aged
6 months–5 years. Among children with laboratory-confirmed
influenza infections, only 28% of those hospitalized and 17%
of those treated as outpatients had a discharge diagnosis of
influenza (34). A study of older nonhospitalized patients
determined that the presence of fever, cough, and acute onset
had a positive predictive value of only 30% for influenza (42).
Among hospitalized older patients with chronic cardiopul-
monary disease, a combination of fever, cough, and illness of
<7 days was 53% predictive for confirmed influenza infection
(43). The absence of symptoms of influenza-like illness (ILI)
does not effectively rule out influenza; among hospitalized
adults with laboratory-confirmed infection, only 51% had
typical ILI symptoms of fever plus cough or sore throat (44).
A study of vaccinated older persons with chronic lung disease
reported that cough was not predictive of laboratory-confirmed
influenza virus infection, although having both fever or fever-
ishness and myalgia had a positive predictive value of 41%
(45). These results highlight the challenges of identifying
influenza illness in the absence of laboratory confirmation and
indicate that the diagnosis of influenza should be considered




In the United States, annual epidemics of influenza typi-
cally occur during the fall or winter months, but the peak of
influenza activity can occur as late as April or May (Table 1).
Influenza-related hospitalizations or deaths can result from
the direct effects of influenza virus infection or from compli-
cations due to underlying cardiopulmonary conditions and
other chronic diseases. Studies that have measured rates of a
clinical outcome without a laboratory confirmation of influ-
enza virus infection (e.g., respiratory illness requiring hospi-
talization during influenza season) to assess the effect of
influenza can be difficult to interpret because of circulation of
other respiratory pathogens (e.g., respiratory syncytial virus)
during the same time as influenza viruses (46–48).
During seasonal influenza epidemics from 1979–1980
through 2000–2001, the estimated annual overall number of
influenza-associated hospitalizations in the United States
ranged from approximately 55,000 to 431,000 per epidemic
(mean: 226,000); the estimated annual number of deaths
attributed to influenza ranged from 8,000 to 68,000 per epi-
demic (mean: 34,000) (1,2). Since the 1968 influenza A
(H3N2) virus pandemic, the number of influenza-associated
hospitalizations typically has been greater during seasonal
influenza epidemics caused by type A (H3N2) viruses than
during seasons in which other influenza virus types or sub-
types have predominated (49). In the United States, the num-
ber of influenza-associated deaths has increased since 1990.
This increase has been attributed in part to the substantial
increase in the number of persons aged >65 years, who are at
increased risk for death from influenza complications (50). In
one study, an average of approximately 19,000 influenza-
associated pulmonary and circulatory deaths per influenza sea-
son occurred during 1976–1990, compared with an average
of approximately 36,000 deaths per season during 1990–1999
(1). In addition, influenza A (H3N2) viruses, which have been
associated with higher mortality (51), predominated in 90%
of influenza seasons during 1990–1999, compared with 57%
of seasons during 1976–1990 (1).
Influenza viruses cause disease among persons in all age
groups (3–5). Rates of infection are highest among children,
but the risks for complications, hospitalizations, and deaths
from influenza are higher among persons aged >65 years, young
children, and persons of any age who have medical condi-
tions that place them at increased risk for complications from
influenza (1,3,6–8,52–55). Estimated rates of influenza-
associated hospitalizations and deaths varied substantially by
age group in studies conducted during different influenza
epidemics (Table 2). During 1990–1999, estimated rates of
influenza-associated pulmonary and circulatory deaths per
100,000 persons were 0.4–0.6 among persons aged 0–49 years,
7.5 among persons aged 50–64 years, and 98.3 among per-
sons aged >65 years (1).
TABLE 1. Month of peak influenza activity* during 31 influenza seasons — United States, 1976–2006
Month
Nov Dec Jan Feb Mar Apr May
No. (%) of years with peak influenza activity 1 (3) 4 (13) 6 (19) 14 (45) 4 (13) 1 (3) 1 (3)
* The peak month of activity was defined as the month with the greatest percentage of respiratory specimens testing positive for influenza virus. Laboratory
data were provided by the U.S. World Health Organization Collaborating Laboratory (CDC, National Center for Immunization and Respiratory Diseases,
unpublished data, 1976–2006).
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TABLE 2. Estimated rates of influenza-associated hospitalization, by age group and risk group for selected studies — United States
Hospitalizations/100,000 persons Hospitalizations/100,000 persons
Study years Population Age group with high-risk conditions without high-risk conditions
1973–1993*† Tennessee Medicaid 0–11 mos 1,900 496–1,038
1–2 yrs 800 186
3–4 yrs 320 86
5–14 yrs 92 41
1992–1997§¶ Two health maintenance organizations 0–23 mos 144–187
2–4 yrs 0–25
5–17 yrs 8–12
1968–1969 Health maintenance organizations 15–44 yrs 56–110 23–25
1970–1971 45–64 yrs 392–635 13–23
1972–1973**†† >65 yrs 399–518 —
1969–1995††§§ Discharge Data <65 yrs — 20–42¶¶ ***
1969–1995†† §§ >65 yrs — 125–228***
1979–2001††† National Hospital Discharge Data All ages — 88§§§
1996–2000¶¶¶ Three health maintenance organizations 18–49 yrs 40 5
50–64 yrs 123 18
>65 yrs 556 187
2000–2001****†††† Two counties <1 yr — 170
1 yr 50
2–<5 yrs 20




2000–2004††††¶¶¶¶¶ Three counties <6 mos 240
6–23 mos 60
24–59 mos 20
2003–2004††††***** 9 states <6 mos 311 118
6–23 mos
1994–2000††††† Health maintenance organization 6–23 mos 213 51
2–4 yrs 142 32




* Sources: Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. Effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl
J Med 2000;342:225–31. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR. Burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr
2000;137:856–64.
† Outcomes were for acute cardiac or pulmonary conditions. The low estimate is for infants aged 6–11 months, and the high estimate is for infants aged 0–5 months.
§ Source: Izurieta HA, Thompson WW, Kramarz P, Mitchel EF Jr, Griffin MR. Influenza and the rates of hospitalization for respiratory disease among infants and young
children. N Engl J Med 2000;342:232–9.
¶ Outcomes were for acute pulmonary conditions. Influenza-attributable hospitalization rates for children at high risk were not included in this study.
** Source: Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798–811.
†† Outcomes were limited to hospitalizations in which either pneumonia or influenza was listed as the first condition on discharge records or included anywhere in the list of
discharge diagnoses.
§§ Source: Simonsen L, Fukuda K, Schonberger LB, Cox NJ. Impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831–7.
¶¶ Persons at high risk and not at high risk for influenza-related complications are combined.
*** The low estimate is the average during influenza A (H1N1) or influenza B-predominate seasons, and the high estimate is the average during influenza A (H3N2)-predominate seasons.
††† Source: Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333–40.
§§§ Outcomes were for rate of primary respiratory and circulatory hospitalizations. Rate for all ages of persons, both with and without high-risk conditions.
¶¶¶ Source: Mullooly JP, Bridges CB, Thompson WW, et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2006;25:846–55.
**** Source: Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial viirus, influenza virus, and
parainfluenza viruses among young children. Pediatrics 2006;113:1758–64.
†††† Laboratory-confirmed influenza virus infection.
§§§§ Source: Ampofo K, Gesteland PH, Bender J, et al. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection.
Pediatrics 2006;118:2409–17.
¶¶¶¶ Source: Poehling KA, Edwards KM, Weinberg GA, et al. The underrecognized burden of influenza in young children. N Engl J Med 2006;355:31–40.
***** Source: Schrag SJ, Shay DK, Gershman K, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children, 2003–2004. Pediatr
Infect Dis J 2006;25:395–400.
††††† Source : O’Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004;113:585–93.
§§§§§ Source: Coffin SE, Zaoutis TE, Rosenquist AB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired
influenza. Pediatrics 2007;119:740–8.
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Children
Rates of influenza-associated hospitalization are higher
among young children than among older children when
influenza viruses are in circulation and similar to rates for other
groups considered at high risk for influenza-related complica-
tions (49,56–61), including persons aged >65 years (57,58).
During 1979–2001, the estimated rate of influenza-
associated hospitalizations in the United States among chil-
dren aged <5 years was approximately 108 hospitalizations
per 100,000 person-years (2). Recent population-based
studies that have measured hospitalization rates for labora-
tory-confirmed influenza in young children have been consis-
tent with studies that analyzed medical discharge data
(29,32–34,60). Annual hospitalization rates for laboratory-
confirmed influenza decrease with increasing age, ranging from
240–720 per 100,000 children aged <6 months to approxi-
mately 20 per 100,000 children aged 2–5 years (34). Estimated
hospitalization rates for young children with high-risk medical
conditions are approximately 250–500 per 100,000 children
(53,55) (Table 2).
Influenza-associated deaths are uncommon among children
but represent a substantial proportion of vaccine-preventable
deaths. An estimated annual average of 92 influenza-related
deaths (0.4 deaths per 100,000 persons) occurred among chil-
dren aged <5 years during the 1990s, compared with 32,651
deaths (98.3 per 100,000 persons) among adults aged >65
years (1). Of 153 laboratory-confirmed influenza-related
pediatric deaths reported during the 2003–04 influenza sea-
son, 96 (63%) deaths were of children aged <5 years and 61
(40%) of children aged <2 years. Among the 149 children
who died and for whom information on underlying health
status was available, 100 (67%) did not have an underlying
medical condition that was an indication for vaccination at
that time (62). In California during the 2003–04 and 2004–
05 influenza seasons, 51% of children with laboratory-con-
firmed influenza who died and 40% of those who required
admission to an intensive care unit had no underlying medi-
cal conditions (63). These data indicate that although deaths
are more common among children with risk factors for influ-
enza complications, the majority of pediatric deaths occur
among children of all age groups with no known high-risk
conditions. The annual number of deaths among children
reported to CDC for the past four influenza seasons has ranged
from 44 during 2004–2005 to 67 during 2006–2007 (CDC,
unpublished data, 2007).
Adults
Hospitalization rates during influenza season are substan-
tially increased for persons aged >65 years. One retrospective
analysis based on data from medical records collected during
1996–2000 estimated that the risk during influenza season
among persons aged >65 years with underlying conditions
that put them at risk for influenza-related complications (i.e.,
one of more of the conditions listed as indications for vacci-
nation) was approximately 56 influenza-associated hospital-
izations per 10,000 persons, compared with approximately
19 per 10,000 healthy elderly persons. Persons aged 50–64
years with underlying medical conditions also were at sub-
stantially increased risk for hospitalizations during influenza
season, compared with healthy adults aged 50–64 years. No
increased risk for influenza-associated hospitalizations was
demonstrated among healthy adults aged 50–64 years or
among those aged 19–49 years, regardless of underlying medi-
cal conditions (52). During 1976–2001, an estimated yearly
average of 32,651 (90%) influenza-related deaths occurred
among adults aged >65 years (1). Risk for influenza-
associated death was highest among the oldest elderly, with
persons aged >85 years 16 times more likely to die from an
influenza-associated illness than persons aged 65–69 years (1).
Limited information is available regarding the frequency and
severity of influenza illness among persons with human
immunodeficiency virus (HIV) infection (64,65). However,
a retrospective study of young and middle-aged women
enrolled in Tennessee’s Medicaid program determined that the
attributable risk for cardiopulmonary hospitalizations among
women with HIV infection was higher during influenza sea-
sons than it was either before or after influenza was circulat-
ing. The risk for hospitalization was higher for HIV-infected
women than it was for women with other underlying medical
conditions (66). Another study estimated that the risk for
influenza-related death was 94–146 deaths per 100,000 per-
sons with acquired immunodeficiency syndrome (AIDS), com-
pared with 0.9–1.0 deaths per 100,000 persons aged 25–54
years and 64–70 deaths per 100,000 persons aged >65 years
(67). Influenza symptoms might be prolonged and the risk
for complications from influenza increased for certain
HIV-infected persons (68–70).
Influenza-associated excess deaths among pregnant women
were reported during the pandemics of 1918–1919 and 1957–
1958 (71–74). Case reports and several epidemiologic studies
also indicate that pregnancy can increase the risk for serious
medical complications of influenza (75–80). The majority of
recent studies that have attempted to assess the effect of influ-
enza on pregnant women have measured changes in excess
hospitalizations for respiratory illness during influenza season
but not laboratory-confirmed influenza hospitalizations. Preg-
nant women have an increased number of medical visits for
respiratory illnesses during influenza season compared with
nonpregnant women (81). Hospitalized pregnant women with
respiratory illness during influenza season have increased
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lengths of stay compared with hospitalized pregnant women
without respiratory illness. For example, rates of hospitaliza-
tion for respiratory illness were twice as common during
influenza season (82). A retrospective cohort study of approxi-
mately 134,000 pregnant women conducted in Nova Scotia
during 1990–2002 compared medical record data for preg-
nant women to data from the same women during the year
before pregnancy. Among pregnant women, 0.4% were hos-
pitalized and 25% visited a clinician during pregnancy for a
respiratory illness. The rate of third-trimester hospital admis-
sions during the influenza season was five times higher than
the rate during the influenza season in the year before preg-
nancy and more than twice as high as the rate during the
noninfluenza season. An excess of 1,210 hospital admissions
in the third trimester per 100,000 pregnant women with
comorbidities and 68 admissions per 100,000 women with-
out comorbidities was reported (83). In one study, pregnant
women with respiratory hospitalizations did not have an
increase in adverse perinatal outcomes or delivery complica-
tions (84), but they did have an increase in delivery complica-
tions in another study (82). However, infants born to women
with laboratory-confirmed influenza during pregnancy do not
have higher rates of low birth weight, congenital abnormali-
ties, or low Apgar scores compared with infants born to
uninfected women (79,85).
Options for Controlling Influenza
The most effective strategy for reducing the effect of influ-
enza is annual vaccination. Strategies that focus on providing
routine vaccination to persons at higher risk for influenza com-
plications have long been recommended, although coverage
among the majority of these groups remains low. Routine vac-
cination of certain persons (e.g., children and HCP) who serve
as a source of influenza virus transmission might provide ad-
ditional protection to persons at risk for influenza complica-
tions and reduce the overall influenza burden. Antiviral drugs
used for chemoprophylaxis or treatment of influenza are ad-
juncts to vaccine but are not substitutes for annual vaccina-
tion. Nonpharmacologic interventions (e.g., advising frequent
handwashing and improved respiratory hygiene) are reason-
able and inexpensive; these strategies have been demonstrated
to reduce respiratory diseases (86) but have not been studied
adequately to determine if they reduce transmission of influ-
enza virus. Similarly, few data are available to assess the effects
of community-level respiratory disease mitigation strategies
(e.g., closing schools, avoiding mass gatherings, or using masks)
on reducing influenza virus transmission during typical sea-
sonal influenza epidemics (87,88).
Influenza Vaccine Efficacy,
Effectiveness, and Safety
Evaluating Influenza Vaccine Efficacy
and Effectiveness Studies
The efficacy (i.e., prevention of illness among vaccinated
persons in controlled trials) and effectiveness (i.e., prevention
of illness in vaccinated populations) of influenza vaccines
depend primarily on the age and immunocompetence of the
vaccine recipient, the degree of similarity between the viruses
in the vaccine and those in circulation, and the outcome
being measured. Influenza vaccine efficacy and effectiveness
studies typically have multiple possible outcome measures,
including the prevention of medically attended acute respira-
tory illness (MAARI), prevention of laboratory-confirmed
influenza virus illness, prevention of influenza or pneumonia-
associated hospitalizations or deaths, seroconversion to vac-
cine strains, or prevention of seroconversion to circulating
influenza virus strains. Efficacy or effectiveness for specific
outcomes such as laboratory-confirmed influenza typically will
be higher than for less specific outcomes such as MAARI
because the causes of MAARI include infections with other
pathogens that influenza vaccination would not be expected
to prevent (89). Observational studies that compare less-
specific outcomes among vaccinated populations to those
among unvaccinated populations are subject to biases that are
difficult to control for during analyses. For example, an
observational study that determines that influenza vaccina-
tion reduces overall mortality might be biased if healthier
persons in the study are more likely to be vaccinated (90).
Randomized controlled trials that measure laboratory-
confirmed influenza virus infections as the outcome are the most
persuasive evidence of vaccine efficacy, but such trials cannot
be conducted ethically among groups recommended to receive
vaccine annually.
Influenza Vaccine Composition
Both LAIV and TIV contain strains of influenza viruses
that are antigenically equivalent to the annually recommended
strains: one influenza A (H3N2) virus, one influenza A
(H1N1) virus, and one influenza B virus. Each year, one or
more virus strains might be changed on the basis of global
surveillance for influenza viruses and the emergence and spread
of new strains. Only the H1N1 strain was changed for the
recommended vaccine for the 2007–08 influenza season, com-
pared with the 2006–07 season (see Recommendations for
Using TIV and LAIV During the 2007–08 Influenza Sea-
son). Viruses for both types of currently licensed vaccines are
grown in eggs. Both vaccines are administered annually to
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provide optimal protection against influenza virus infection
(Table 3) Both TIV and LAIV are widely available in the
United States. Although both types of vaccines are expected
to be effective, the vaccines differ in several aspects (Table 3)
Major Differences Between TIV
and LAIV
During the preparation of TIV, the vaccine viruses are made
noninfectious (i.e., inactivated or killed) (91). Only subvirion
and purified surface antigen preparations of TIV (often
referred to as “split” and subunit vaccines, respectively) are
available in the United States. TIV contains killed viruses and
thus cannot cause influenza. LAIV contains live, attenuated
viruses and therefore has the potential to produce mild signs
or symptoms related to attenuated influenza virus infection.
LAIV is administered intranasally by sprayer, whereas TIV is
administered intramuscularly by injection. LAIV is currently
approved only for use among healthy persons aged 5–49 years;
TIV is approved for use among persons aged >6 months,
including those who are healthy and those with chronic medi-
cal conditions (Table 3).
TABLE 3. Live, attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine (TIV)
Factor LAIV TIV
Route of administration Intranasal spray Intramuscular injection
Type of vaccine Live virus Killed virus
No. of included virus strains
3 (2 influenza A, 1 influenza B) 3 (2 influenza A, 1 influenza B)
Vaccine virus strains updated Annually Annually
Frequency of administration Annually* Annually*
Approved age and risk groups§ Healthy persons aged 5–49 yrs Persons aged >6 mos
Interval between 2 doses recommended for children aged >6 mos–8 years 6–10 weeks 4 weeks
who are receiving influenza vaccine for the first time
Can be administered to family members or close contacts of Yes Yes
immunosuppressed persons not requiring a protected environment
Can be administered to family members or close contacts of No Yes
immunosuppressed persons requiring a protected environment
(e.g., hematopoietic stem cell transplant recipient)
Can be administered to family members or close contacts of persons Yes Yes
at high risk but not severely immunosuppressed
Can be simultaneously administered with other vaccines Yes¶ Yes**
If not simultaneously administered, can be administered within Prudent to space 4 weeks apart Yes
4 wks of another live vaccine
If not simultaneously administered, can be administered within Yes Yes
4 wks of an inactivated vaccine
* Children aged >6 months who have never received influenza vaccine before should receive 2 doses. Those who received only 1 dose in their first year of
vaccination should receive 2 doses in the following year.
† LAIV is currently licensed to be administered only to persons aged >5 years.
§ Annual vaccination against influenza is recommended for 1) all persons, including school-aged children, who want to reduce the risk of becoming ill with
influenza or of transmitting influenza to others; 2) all children aged 6–59 months (i.e., 6 months–4 years); all persons aged >50 years; 3) children and
adolescents (aged 6 months–18 years) receiving long-term aspirin therapy who therefore might be at risk for experiencing Reye syndrome after influenza
virus infection; 4) women who will be pregnant during the influenza season; 5) adults and children who have chronic pulmonary (including asthma),
cardiovascular (except hypertension), renal, hepatic, hematologic or metabolic disorders (including diabetes mellitus); 6) adults and children who have
immunosuppression (including immunosuppression caused by medications or by human immunodeficiency virus ); 7) adults and children who have any
condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or other neuromuscular disorders) that can compromise respiratory function or
the handling of respiratory secretions or that can increase the risk for aspiration; 8) residents of nursing homes and other chronic-care facilities; 9) health-
care workers; 10) healthy household contacts (including children) and caregivers of children aged <5 years and adults aged >50 years, with particular focus
on vaccinating contacts of children aged <6 months; and 11) healthy household contacts (including children) and caregivers of persons with medical
conditions that put them at higher risk for severe complications from influenza. However, no vaccine is approved for children aged <6 months.
¶ No data are available regarding effect on safety or efficacy.
** Inactivated influenza vaccine coadministration has been evaluated systematically only among adults with pneumococcal polysaccharide vaccine.
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Correlates of Protection after
Vaccination
Immune correlates of protection against influenza infection
after vaccination include serum hemagglutination inhibition
antibody and neutralization antibody (15,92). Increased lev-
els of antibody induced by vaccination decrease the risk for
illness caused by strains that are antigenically similar to those
strains of the same type or subtype included in the vaccine
(93–96). Although high titers of these antibodies correlate
with protection from clinical infection, certain vaccinated
persons with low levels of antibody after vaccination also are
protected. The majority of healthy children and adults have
high titers of antibody after vaccination (94,97). However, in
certain studies, antibody levels in certain participants declined
below levels considered protective during the year after vacci-
nation, even when the current influenza vaccine contained
one or more antigens administered in previous years (98,99).
Other immunologic correlates of protection that might best
indicate clinical protection after receipt of an intranasal vac-
cine such as LAIV (e.g., mucosal antibody) are more difficult
to measure (91,100).
Immunogenicity, Efficacy,
and Effectiveness of TIV
Children
Children aged >6 months typically have protective levels of
anti-influenza antibody against specific influenza virus strains
after influenza vaccination (92,97,101–106). Children aged
6 months–8 years who have never been vaccinated previously
require 2 doses of TIV separated in time by >4 weeks to
induce an optimal serum antibody response. A study assess-
ing protective antibody responses after 1 and 2 doses of vac-
cine among children aged 5–8 years who never were vaccinated
previously indicated that children who received 2 doses were
substantially more likely than those who received 1 dose to
have a protective antibody response (107). The proportion
that had a protective antibody response against the H1N1
antigen and the H3N2 antigen increased from 67% and 92%,
respectively, after the first dose to 93% and 97%, respectively,
after the second dose. However, 36% of children who
received 2 doses did not have a protective antibody response to
the influenza B antigen (107).
When the vaccine antigens do not change from one season
to the next, priming young children with a single dose of vac-
cine in the spring followed by a second dose in the fall engen-
ders similar antibody responses compared with a regimen of 2
doses in the fall (108). In consecutive years, when vaccine
antigens do change, young children who received only 1 dose
of vaccine in their first year of vaccination are less likely to
have protective antibody responses when administered only a
single dose during their second year of vaccination, compared
with children who received 2 doses in their first year of vacci-
nation (109,110). An open-label, nonrandomized study com-
pared children aged 6–23 months who received 1 dose of
vaccine during the 2003–04 influenza season and a second
dose of a different vaccine during the 2004–05 season with
children who received 2 doses of the same vaccine during the
2004–05 season. The proportion that had protective antibody
levels against the H3N2 antigen (changed in the second year)
or the H1N1 antigen (unchanged) was similar. However, 27%
of children who had received only 1 dose of influenza vaccine
during 2003–2004 had a protective antibody response to a
single dose of the 2004–2005 vaccine influenza B virus anti-
gen (changed from the previous year), compared with 86% of
children who received 2 doses of the 2004–2005 vaccine in
their first year of vaccination (110).
The antibody response among children at high risk for influ-
enza-related complications might be lower than those typically
reported among healthy children (111,112). However, antibody
responses among children with asthma are similar to those of
healthy children and are not substantially altered during asthma
exacerbations requiring prednisone treatment (113).
Multiple studies have demonstrated vaccine efficacy among
children aged >6 months, although efficacy estimates have
varied. In a randomized trial conducted during five influenza
seasons (1985–1990) in the United States among children aged
1–15 years, annual vaccination reduced laboratory-confirmed
influenza A substantially (77%–91%) (94). A limited 1-year
placebo-controlled study reported vaccine efficacy of 56%
among healthy children aged 3–9 years and 100% among
healthy children and adolescents aged 10–18 years (114).
A retrospective study conducted among approximately 30,000
children aged 6 months–8 years during an influenza season
(2003–04) with a suboptimal vaccine match indicated vac-
cine effectiveness of 51% against medically attended, clini-
cally diagnosed pneumonia or influenza (i.e., no laboratory
confirmation of influenza) among fully vaccinated children,
and 49% among approximately 5,000 children aged 6–23
months (115). Another retrospective study of similar size con-
ducted during the same influenza season in Denver but lim-
ited to healthy children aged 6–21 months estimated clinical
effectiveness of 2 TIV doses to be 87% against pneumonia or
influenza-related office visits (116). Among children, TIV
efficacy might increase with age (94,117).
In a nonrandomized controlled trial among children aged
2–6 years and 7–14 years who had asthma, vaccine efficacy
was 54% and 78% against laboratory-confirmed influenza type
A infection and 22% and 60% against laboratory-confirmed
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influenza type B infection, respectively. Vaccinated children
aged 2–6 years with asthma did not have substantially fewer
type B influenza virus infections compared with the control
group in this study (118). Vaccination also might provide pro-
tection against asthma exacerbations (119); however, other
studies of children with asthma have not demonstrated
decreased exacerbations (120). Because of the recognized
influenza-related disease burden among children with other
chronic diseases or immunosuppression and the long-
standing recommendation for vaccination of these children,
randomized placebo-controlled studies to study efficacy in
these children have not been conducted because of ethical
considerations.
TIV has been demonstrated to reduce acute otitis media.
Two studies have reported that TIV decreases influenza-
associated otitis media approximately 30% among children
with mean ages of 20 and 27 months, respectively (121,122).
However, a large study conducted among children with a mean
age of 14 months did not provide evidence of TIV efficacy
against acute otitis media (123), although efficacy was 66%
against culture-confirmed influenza illness. Influenza vaccine
efficacy against acute otitis media, which is caused by a vari-
ety of pathogens and is not typically diagnosed using influ-
enza virus culture, would be expected to be relatively low
because of the nonspecificity of the clinical outcome.
Vaccine Effectiveness for Children Aged
6 Months–8 Years Receiving Influenza
Vaccine for the First Time
Among children aged <8 years who have never received
influenza vaccine previously and who received only 1 dose of
influenza vaccine in their first year of vaccination, vaccine
effectiveness is lower compared with children who receive
2 doses in their first year of being vaccinated. Two recent,
large retrospective studies of young children who had received
only 1 dose of TIV in their first year of being vaccinated
determined that no decrease was observed in ILI-related
office visits compared with unvaccinated children (115,116).
Similar results were reported in a case-control study of chil-
dren aged 6–59 months (124).
When the vaccine antigens do not change from one season
to the next, priming with a single dose of vaccine in the spring
followed by a dose in the fall provides a degree of protection
against ILI but with substantially lower efficacy compared with
a regimen that provides 2 doses in the fall. One study conducted
over two consecutive seasons in which the vaccine antigens did
not change estimated 62% effectiveness against ILI for healthy
children who had received 1 dose in the spring and a second the
following fall, compared with 82% for those who received 2 doses
separated by >4 weeks, both in the fall (116).
Adults Aged <65 Years
TIV is highly immunogenic in healthy adults aged <65 years.
Limited or no increase in antibody response is reported among
adults when a second dose is administered during the same
season (125–129). When the vaccine and circulating viruses
are antigenically similar, TIV prevents laboratory-confirmed
influenza illness among approximately 70%–90% of healthy
adults aged <65 years in randomized controlled trials (129–
132). Vaccination of healthy adults also has resulted in
decreased work absenteeism and decreased use of health-care
resources, including use of antibiotics, when the vaccine and
circulating viruses are well-matched (129–131,133–135).
Efficacy against laboratory-confirmed influenza illness was
50%–77% in studies conducted during different influenza
seasons when the vaccine strains were antigenically dissimilar
to the majority of circulating strains (129,131,135–137). How-
ever, protection among healthy adults against influenza-
related hospitalization, measured in the most recent of these
studies, was 90% (137).
In certain studies, persons with certain chronic diseases have
lower serum antibody responses after vaccination compared
with healthy young adults and thus can remain susceptible to
influenza virus infection and influenza-related upper respira-
tory tract illness (138–140). Vaccine efficacy among adults
aged <65 years who are at risk for influenza complications is
typically lower than that reported for healthy adults. In a case-
control study conducted during 2003–2004, when the vac-
cine was a suboptimal antigenic match to many circulating
virus strains, effectiveness for prevention of laboratory-
confirmed influenza illness among adults aged 50–64 years
with high risk conditions was 48%, compared with 60% for
healthy adults (137). Effectiveness against hospitalization
among adults aged 50–64 years with high-risk conditions was
36%, compared with 90% efficacy among healthy adults in
that age range (137).
Studies using less specific outcomes, without laboratory
confirmation of influenza virus infection, typically have dem-
onstrated substantial reductions in hospitalizations or deaths
among adults with risk factors for influenza complications. In
a case-control study conducted in Denmark during 1999–
2000, vaccination reduced deaths attributable to any cause
78% and reduced hospitalizations attributable to respiratory
infections or cardiopulmonary diseases 87% (141). Benefit
was reported after the first vaccination and increased with
subsequent vaccinations in subsequent years (142). Among
patients with diabetes mellitus, vaccination was associated with
a 56% reduction in any complication, a 54% reduction in
hospitalizations, and a 58% reduction in deaths (143). Cer-
tain experts have noted that the substantial effects on mor-
12 MMWR July 13, 2007
bidity and mortality among those who received influenza vac-
cination in these observational studies should be interpreted
with caution because of the difficulties in ensuring that those
who received vaccination had similar baseline health status as
those who did not (90). One meta-analysis of published stud-
ies did not determine sufficient evidence to conclude that per-
sons with asthma benefit from vaccination (144).
However, a meta-analysis that examined efficacy among per-
sons with chronic obstructive pulmonary disease identified evi-
dence of benefit from vaccination (145).
TIV produces adequate antibody concentrations against in-
fluenza among vaccinated HIV-infected persons who have mini-
mal AIDS-related symptoms and high CD4+ T-lymphocyte cell
counts (146–148). Among persons who have advanced HIV
disease and low CD4+ T-lymphocyte cell counts, TIV might
not induce protective antibody titers (148,149); a second dose
of vaccine does not improve the immune response in these
persons (149,150). A randomized, placebo-controlled trial
determined that TIV was highly effective in preventing
symptomatic, laboratory-confirmed influenza virus infection
among HIV-infected persons with a mean of 400 CD4+
T-lymphocyte cells/mm3; however, only a limited number of
persons with CD4+ T-lymphocyte cell counts of <200 were
included in that study (150). A nonrandomized study of HIV-
infected persons determined that influenza vaccination was most
effective among persons with >100 CD4+ cells and among those
with <30,000 viral copies of HIV type-1/mL (70).
Pregnant women have protective concentrations of anti-
influenza antibodies after vaccination (151,152). Passive trans-
fer of anti-influenza antibodies that might provide protection
from vaccinated women to neonates has been reported
(151,153–155). A retrospective, clinic-based study conducted
during 1998–2003 reported a nonsignificant trend towards
fewer episodes of MAARI during one influenza season among
vaccinated women compared with unvaccinated women and
substantially fewer episodes of MAARI during the peak influ-
enza season (152). However, a retrospective study conducted
during 1997–2002 that used clinical records data did not
observe a reduction in ILI among vaccinated pregnant women
or their infants (156). In another study conducted during
1995–2001, medical visits for respiratory illness among the
infants were not substantially reduced (157). However, stud-
ies of influenza vaccine efficacy among pregnant women have
not included specific outcomes such as laboratory-confirmed
influenza.
Older Adults
Lower postvaccination anti-influenza antibody concentra-
tions have been reported among certain older persons com-
pared with younger adults (139–140). A randomized trial
among noninstitutionalized persons aged >60 years reported
a vaccine efficacy of 58% against influenza respiratory illness
but indicated that efficacy might be lower among those aged
>70 years (158). Among elderly persons not living in nursing
homes or similar chronic-care facilities, influenza vaccine is
30%–70% effective in preventing hospitalization for pneu-
monia and influenza (159,160). Influenza vaccination reduces
the frequency of secondary complications and reduces the risk
for influenza-related hospitalization and death among adults
aged >65 years with and without high-risk medical condi-
tions (e.g., heart disease and diabetes) (160–165). Influenza
vaccine effectiveness in preventing MAARI among the elderly
in nursing homes has been estimated at 20%–40%, but vac-
cination can be as much as 80% effective in preventing influ-
enza-related death (165–168).
Elderly persons typically have a diminished immune response
to influenza vaccination compared with young healthy adults,
suggesting that immunity might be of shorter duration and
less likely to extend to a second season (169). Infections among
the vaccinated elderly might be related to an age-related reduc-




The composition of TIV varies according to manufacturer,
and package inserts should be consulted. TIV formulations in
multidose vials typically contain the vaccine preservative thime-
rosal; preservative-free single dose preparations also are avail-
able. TIV should be stored at 35°F–46°F (2°C–8°C) and
should not be frozen. TIV that has been frozen should be
discarded. Dosage recommendations and schedules vary
according to age group (Table 4). Vaccine prepared for a pre-
vious influenza season should not be administered to provide
protection for any subsequent season.
The intramuscular route is recommended for TIV. Adults
and older children should be vaccinated in the deltoid muscle.
A needle length of >1 inch (>25 mm) should be considered
for persons in these age groups because needles of <1 inch
might be of insufficient length to penetrate muscle tissue in
certain adults and older children (170). When injecting into
the deltoid muscle among children with adequate deltoid
muscle mass, a needle length of 7/8–1.25 inches is recom-
mended (171).
Infants and young children should be vaccinated in the
anterolateral aspect of the thigh. A needle length of 7/8–1 inch
should be used for children aged <12 months for intramuscu-
lar vaccination into the anterolateral thigh.
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Adverse Events after Receipt of TIV
In placebo-controlled studies among adults, the most fre-
quent side effect of vaccination was soreness at the vaccina-
tion site (affecting 10%–64% of patients) that lasted <2 days
(130,172,173). These local reactions typically were mild and
rarely interfered with the person’s ability to conduct usual daily
activities. One study (112) reported that 20%–28% of chil-
dren with asthma aged 9 months–18 years had local pain and
swelling at the site of influenza vaccination, and another study
(103) reported that 23% of children aged 6 months–4 years
with chronic heart or lung disease had local reactions.
A blinded, randomized, cross-over study of 1,952 adults and
children with asthma demonstrated that only self-reported
“body aches” were reported more frequently after TIV (25.1%)
than placebo-injection (20.8%) (174). However, a placebo-
controlled trial of TIV indicated no difference in local reac-
tions among 53 children aged 6 months–6 years with high-risk
medical conditions or among 305 healthy children aged
3–12 years (104). A recent retrospective study using medical
records data from approximately 45,000 children aged
6–23 months provided evidence supporting overall safety of
TIV in this age group. Vaccination was not associated with
statistically significant increases in any medically attended
outcome, and 13 diagnoses, including acute upper respira-
tory illness, otitis media and asthma, were significantly less
common (175).
Fever, malaise, myalgia, and other systemic symptoms can
occur after vaccination with inactivated vaccine and most
often affect persons who have had no previous exposure to
the influenza virus antigens in the vaccine (e.g., young chil-
dren) (176,177). These reactions begin 6–12 hours after vac-
cination and can persist for 1–2 days. Recent placebo-
controlled trials demonstrate that among older persons and
healthy young adults, administration of split-virus influenza
vaccine is not associated with higher rates of systemic symp-
toms (e.g., fever, malaise, myalgia, and headache) when com-
pared with placebo injections (129,172,173,178).
In a randomized cross-over study of children and adults with
asthma, no increase in asthma exacerbations was reported for
either age group (174). An analysis of 215,600 children aged
<18 years and 8,476 children aged 6–23 months enrolled in
one of five health maintenance organizations (HMOs)
during 1993–1999 reported no increase in biologically plau-
sible, medically attended events during the 2 weeks after inac-
tivated influenza vaccination, compared with control periods
3–4 weeks before and after vaccination (179). In a study of
791 healthy children aged 1–15 years (94), postvaccination
fever was noted among 11.5% of those aged 1–5 years, 4.6%
among those aged 6–10 years, and 5.1% among those aged
11–15 years.
Among children with high-risk medical conditions, one
study of 52 children aged 6 months–3 years reported fever
among 27% and irritability and insomnia among 25% (103);
TABLE 4. Approved influenza vaccines for different age groups — United States, 2007–08 season
Thimerosal
Trade mercury content
Vaccine name Manufacturer Presentation (mcg Hg/0.5 mL dose) Age group No. of doses Route
TIV* Fluzone® Sanofi Pasteur 0.25-mL prefilled syringe 0 6–35 mos 1 or 2† Intramuscular§
0.5-mL prefilled syringe 0 >36 mos 1 or 2† Intramuscular§
0.5 mL vial 0 >36 mos 1 or 2† Intramuscular§
5.0-mL multidose vial 25 >6 mos 1 or 2† Intramuscular§
TIV* Fluvirin™ Novartis Vaccine 5.0-mL multidose vial 24.5 >4 yrs 1 or 2† Intramuscular§
TIV* Fluarix™ GlaxoSmithKline 0.5-mL prefilled syringe <1.0 >18 yrs 1 Intramuscular§
TIV* FluLuval™ GlaxoSmithKline 5.0-mL multidose vial 25 >18 yrs 1 Intramuscular§
LAIV¶ FluMist™** MedImmune 0.2-mL sprayer 0 5–49 yrs 1 or 2†† Intranasal
* Trivalent inactivated vaccine (TIV). A 0.5-mL dose contains 15 mcg each of A/Solomon Islands/3/2006 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and
B/Malaysia/2506/2004-like antigens.
† Two doses administered at least 1 month apart are recommended for children aged 6 months–8 years who are receiving TIV for the first time and those
who only received 1 dose in their first year of vaccination should receive 2 doses in the following year.
§ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolat-
eral aspect of the thigh.
¶ Live attenuated influenza vaccine (LAIV).
** FluMist dosage and storage requirements have changed for the 2007–08 influenza season. FluMist is now shipped to end users at 35°F–46°F (2°C–8°C).
LAIV should be stored at 35°F–46°F (2°C–8°C) upon receipt and should remain at that temperature until the expiration date is reached. The dose is 0.2 mL,
divided equally between each nostril.
†† Two doses administered at least 6 weeks apart are recommended for children aged 5–8 years who are receiving LAIV for the first time, and those who
received only 1 dose in their first year of vaccination should receive 2 doses in the following year.
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and a study among 33 children aged 6–18 months reported
that one child had irritability and one had a fever and seizure
after vaccination (180). No placebo comparison group was
used in these studies.
Data regarding potential adverse events after influenza vac-
cination are available from the Vaccine Adverse Event Report-
ing System (VAERS). During January 1991–June 2006, of
25,805 reports of adverse events received by VAERS, 5,727
(22%) concerned children aged <18 years, including 1,070
(4%) children aged 6–23 months (CDC, unpublished data,
2005). The number of influenza vaccine doses received by
children during this entire period is unknown. A recently pub-
lished review of VAERS reports submitted after administra-
tion of TIV to children aged 6–23 months documented that
the most frequently reported adverse events were fever, rash,
injection-site reactions, and seizures; the majority of the lim-
ited number of reported seizures appeared to be febrile (181).
Because of the limitations of passive reporting systems, deter-
mining causality for specific types of adverse events, with the
exception of injection-site reactions, usually is not possible
using VAERS data alone. However, a population-based study
of TIV safety in children aged 6–23 months who were vacci-
nated during 1993–1999 identified no adverse events that had
a plausible relationship to vaccination (182).
Immediate and presumably allergic reactions (e.g., hives,
angioedema, allergic asthma, and systemic anaphylaxis)
occur rarely after influenza vaccination (183,184). These
reactions probably result from hypersensitivity to certain vac-
cine components; the majority of reactions probably are caused
by residual egg protein. Although current influenza vaccines
contain only a limited quantity of egg protein, this protein
can induce immediate hypersensitivity reactions among per-
sons who have severe egg allergy. Manufacturers use a variety
of different compounds to inactivate influenza viruses and
add antibiotics to prevent bacterial contamination. Package
inserts should be consulted for additional information.
Persons who have had hives or swelling of the lips or tongue,
or who have experienced acute respiratory distress or who
collapse after eating eggs should consult a physician for
appropriate evaluation to help determine if vaccine should be
administered. Persons who have documented immunoglobu-
lin E (IgE)-mediated hypersensitivity to eggs, including those
who have had occupational asthma related to egg exposure or
other allergic responses to egg protein, also might be at
increased risk for allergic reactions to influenza vaccine, and
consultation with a physician before vaccination should be
considered (185–187).
Hypersensitivity reactions to vaccine components can
occur but are rare. Although exposure to vaccines containing
thimerosal can lead to hypersensitivity, the majority of
patients do not have reactions to thimerosal when it is admin-
istered as a component of vaccines, even when patch or intra-
dermal tests for thimerosal indicate hypersensitivity (188,189).
When reported, hypersensitivity to thimerosal typically has
consisted of local delayed hypersensitivity reactions (188).
TIV Safety for Persons with HIV
Infection
Data demonstrating safety of TIV for HIV-infected per-
sons are limited, but no evidence exists that vaccination has a
clinically important impact on HIV infection or immuno-
competence. One study demonstrated a transient (i.e., 2–4
week) increase in HIV RNA (ribonucleic acid) levels in one
HIV-infected person after influenza virus infection (190).
Studies have demonstrated a transient increase in replication
of HIV-1 in the plasma or peripheral blood mononuclear cells
of HIV-infected persons after vaccine administration
(148,191). However, more recent and better-designed studies
have not documented a substantial increase in the replication
of HIV (192–195). CD4+ T-lymphocyte cell counts or pro-
gression of HIV disease have not been demonstrated to change
substantially after influenza vaccination among HIV-infected
persons compared with unvaccinated HIV-infected persons
(148,196). Limited information is available concerning the
effect of antiretroviral therapy on increases in HIV RNA
levels after either natural influenza virus infection or influ-
enza vaccination (64,197).
Guillain-Barré Syndrome and TIV
Guillain-Barré Syndrome (GBS) has an annual incidence
of 10–20 cases per 1 million adults (198). Substantial evi-
dence exists that multiple infectious illnesses, most notably
Campylobacter jejuni gastrointestinal infections and upper res-
piratory tract infections, are associated with GBS (199–201).
The 1976 swine influenza vaccine was associated with an
increased frequency of GBS (202,203), estimated at one case
of GBS per 100,000 persons vaccinated. The risk for influ-
enza vaccine-associated GBS was higher among persons aged
>25 years than among persons aged <25 years (204). How-
ever, obtaining strong epidemiologic evidence for a possible
limited increase in risk for a rare condition with multiple causes
is difficult, and evidence for a causal relationship between sub-
sequent vaccines prepared from other influenza viruses and
GBS has not been consistent.
None of the studies conducted using influenza vaccines other
than the 1976 swine influenza vaccine have demonstrated a
substantial increase in GBS associated with influenza vaccines.
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During three of four influenza seasons studied during 1977–
1991, the overall relative risk estimates for GBS after influ-
enza vaccination were elevated slightly, but they were not
statistically significant in any of these studies (205–207). How-
ever, in a study of the 1992–93 and 1993–94 seasons, the
overall relative risk for GBS was 1.7 (CI = 1.0–2.8; p = 0.04)
during the 6 weeks after vaccination, representing approxi-
mately one additional case of GBS per 1 million persons vac-
cinated; the combined number of GBS cases peaked 2 weeks
after vaccination (202). Results of a study that examined
health-care data from Ontario, Canada, during 1992–2004
demonstrated a small but statistically significant temporal
association between receiving influenza vaccination and sub-
sequent hospital admission for GBS. However, no increase in
cases of GBS at the population level was reported after intro-
duction of a mass public influenza vaccination program in
Ontario beginning in 2000 (208). Recent data from VAERS
have documented decreased reporting of GBS occurring after
vaccination across age groups over time, despite overall
increased reporting of other, non-GBS conditions occurring
after administration of influenza vaccine (203). Cases of GBS
after influenza virus infection have been reported, but no other
epidemiologic studies have documented such an association
(209,210).
If GBS is a side effect of influenza vaccines other than 1976
swine influenza vaccine, the estimated risk for GBS is based
on the few studies that have demonstrated an association be-
tween vaccination and GBS is low (i.e., approximately one
additional case per 1 million persons vaccinated). The poten-
tial benefits of influenza vaccination in preventing serious ill-
ness, hospitalization, and death substantially outweigh these
estimates of risk for vaccine-associated GBS. No evidence in-
dicates that the case fatality ratio for GBS differs among vac-
cinated persons and those not vaccinated.
Use of TIV among Patients with
a History of GBS
The incidence of GBS among the general population is low,
but persons with a history of GBS have a substantially greater
likelihood of subsequently experiencing GBS than persons
without such a history (198). Thus, the likelihood of coinci-
dentally experiencing GBS after influenza vaccination is
expected to be greater among persons with a history of GBS
than among persons with no history of this syndrome. Whether
influenza vaccination specifically might increase the risk for
recurrence of GBS is unknown. However, avoiding vaccinat-
ing persons who are not at high risk for severe influenza com-
plications and who are known to have experienced GBS within
6 weeks after a previous influenza vaccination is prudent. As
an alternative, physicians might consider using influenza an-
tiviral chemoprophylaxis for these persons. Although data are
limited, the established benefits of influenza vaccination might
outweigh the risks for many persons who have a history of
GBS and who are also at high risk for severe complications
from influenza.
Vaccine Preservative (Thimerosal)
in Multidose Vials of TIV
Thimerosal, a mercury-containing anti-bacterial compound,
has been used as a preservative in vaccines since the 1930s
(211) and is used in multidose vial preparations of TIV to
reduce the likelihood of bacterial contamination. No scien-
tific evidence indicates that thimerosal in vaccines, including
influenza vaccines, is a cause of adverse events in vaccine
recipients or to children born to women who received vaccine
during pregnancy. In fact, evidence is accumulating that
supports the absence of any risk for neurodevelopment disor-
ders or other harm resulting from exposure to thimerosal-
containing vaccines (212–216). However, continuing public
concern about exposure to mercury in vaccines is a potential
barrier to achieving higher vaccine coverage levels and reduc-
ing the burden of vaccine-preventable diseases. The U.S. Public
Health Service and other organizations have recommended
that efforts be made to eliminate or reduce the thimerosal
content in vaccines as part of a strategy to reduce mercury
exposures from all sources (212,214,216). Since mid-2001,
vaccines routinely recommended for infants aged <6 months
in the United States have been manufactured either without
or with greatly reduced (trace) amounts of thimerosal. As a
result, a substantial reduction in the total mercury exposure
from vaccines for infants and children already has been
achieved (171).
The benefits of influenza vaccination for all recommended
groups, including pregnant women and young children, out-
weigh the unproven risk from thimerosal exposure through
vaccination. The risks for severe illness from influenza virus
infection are elevated among both young children and preg-
nant women, and vaccination has been demonstrated to
reduce the risk for severe influenza illness and subsequent medi-
cal complications. In contrast, no scientifically conclusive evi-
dence has demonstrated harm from exposure to vaccine
containing thimerosal preservative. For these reasons, persons
recommended to receive TIV may receive any age- and risk
factor–appropriate vaccine preparation, depending on avail-
ability. ACIP and other federal agencies and professional medi-
cal organizations continue to support efforts to provide
thimerosal preservative–free vaccine options.
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Nonetheless, certain states have enacted legislation banning
the administration of vaccines containing mercury; the provi-
sions defining mercury content vary (217). LAIV and many
of the single dose vial or syringe preparations of TIV are thime-
rosal-free, and the number of influenza vaccine doses that do
not contain thimerosal as a preservative is expected to increase
(see Table 4). However, these laws may present a barrier to
vaccination unless influenza vaccines that do not contain
thimerosal as a preservative are easily available in those states.
The U.S. vaccine supply for infants and pregnant women
is in a period of transition during which the availability of
thimerosal-reduced or thimerosal-free vaccine intended for
these groups is being expanded by manufacturers as a feasible
means of further reducing an infant’s cumulative exposure to
mercury. Other environmental sources of mercury exposure
are more difficult or impossible to avoid or eliminate (212).
LAIV Dosage, Administration,
and Storage
Each dose of LAIV contains the same three antigens used in
TIV for the influenza season. However, the antigens are con-
stituted as live, attenuated, cold-adapted, temperature-
sensitive vaccine viruses. Additional components of LAIV
include stabilizing buffers containing monosodium glutamate,
hydrolyzed porcine gelatin, arginine, sucrose, and phosphate.
LAIV does not contain thimerosal. LAIV is made from
attenuated viruses and does not cause systemic symptoms of
influenza in vaccine recipients although a minority of recipi-
ents experience effects of intranasal vaccine administration or
local viral replication (e.g., nasal congestion) (218).
In January 2007, a new formulation of LAIV (also sold under
the brand name FluMist™) was licensed that will replace the
older formulation for the 2007–08 influenza season. Com-
pared with the formulation sold previously, the principal dif-
ferences are the temperature at which LAIV is shipped and
stored after delivery to the clinic and the amount of vaccine
administered. LAIV is intended for intranasal administration
only and should not be administered by the intramuscular,
intradermal, or intravenous route. LAIV is not approved for
vaccination of children aged <5 years or adults aged >49 years.
The new formulation of LAIV is supplied in a prefilled, single-
use sprayer containing 0.2 mL of vaccine. Approximately 0.1
mL (i.e., half of the total sprayer contents) is sprayed into the
first nostril while the recipient is in the upright position. An
attached dose-divider clip is removed from the sprayer to ad-
minister the second half of the dose into the other nostril.
The new formulation of LAIV is shipped to end users at 35°F–
46°F (2°C–8°C). LAIV should be stored at 35°F–46°F (2°C–
8°C) upon receipt, and can remain at that temperature until
the expiration date is reached (218).
Shedding, Transmission, and Stability
of Vaccine Viruses
Available data indicate that both children and adults vacci-
nated with LAIV can shed vaccine viruses after vaccination,
although in lower amounts than occur typically with shed-
ding of wild-type influenza viruses. In rare instances, shed
vaccine viruses can be transmitted from vaccine recipients to
nonvaccinated persons. However, serious illnesses have not
been reported among unvaccinated persons who have been
infected inadvertently with vaccine viruses.
One study of children aged 8–36 months in a child care
center assessed transmissibility of vaccine viruses from 98 vac-
cinated to 99 unvaccinated subjects; 80% of vaccine recipi-
ents shed one or more virus strains (mean duration: 7.6 days).
One influenza type B vaccine strain isolate was recovered from
a placebo recipient and was confirmed to be vaccine-type virus.
The type B isolate retained the cold-adapted, temperature-
sensitive, attenuated phenotype, and it possessed the same
genetic sequence as a virus shed from a vaccine recipient who
was in the same play group. The placebo recipient from whom
the influenza type B vaccine strain was isolated did not expe-
rience any serious clinical events. The estimated probability
of acquiring vaccine virus after close contact with a single LAIV
recipient in this child care population was 0.6%–2.4% (219).
One study assessing shedding of vaccine viruses in 20 healthy
vaccinated adults aged 18–49 years demonstrated that the
majority of shedding occurred within the first 3 days after
vaccination, although one subject was noted to shed virus on
day 7 after vaccine receipt. Duration or type of symptoms
associated with receipt of LAIV did not correlate with dura-
tion of shedding of vaccine viruses (220). Another study
assessing shedding of vaccine viruses in 14 healthy adults aged
18–49 years indicated that 50% of these adults had viral anti-
gen detected by direct immunofluorescence or rapid antigen
tests within 7 days of vaccination. The majority of viral shed-
ding was detected on day 2 or 3 (221). Vaccine strain virus
was detected from nasal secretions in one (2%) of 57 HIV-
infected adults who received LAIV, none of 54 HIV-negative
participants (222), and three (13%) of 23 HIV-infected chil-
dren compared with seven (28%) of 25 children who were
not HIV-infected (223). No participants in these studies shed
virus beyond 10 days after receipt of LAIV. The possibility of
person-to-person transmission of vaccine viruses was not
assessed in these studies (220–223).
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In clinical trials, viruses shed by vaccine recipients have been
phenotypically stable. In one study, nasal and throat swab speci-
mens were collected from 17 study participants for 2 weeks
after vaccine receipt (224). Virus isolates were analyzed by
multiple genetic techniques. All isolates retained the LAIV
genotype after replication in the human host, and all retained
the cold-adapted and temperature-sensitive phenotypes. A
study conducted in a child care setting demonstrated that lim-
ited genetic change occurred in the LAIV strains following
replication in the vaccine recipients (225).
Immunogenicity, Efficacy,
and Effectiveness of LAIV
The immunogenicity of the approved LAIV has been
assessed in multiple studies conducted among children and
adults (94,226–232). LAIV virus strains replicate primarily
in nasopharyngeal epithelial cells. The protective mechanisms
induced by vaccination with LAIV are not understood com-
pletely but appear to involve both serum and nasal secretory
antibodies. No single laboratory measurement closely corre-
lates with protective immunity induced by LAIV (227).
Healthy Children
A randomized, double-blind, placebo-controlled trial among
1,602 healthy children aged 15–71 months assessed the effi-
cacy of LAIV against culture-confirmed influenza during two
seasons (233,234). This trial included a subset of children
aged 60–71 months who received 2 doses in the first season.
In season one (1996–97), when vaccine and circulating virus
strains were well-matched, efficacy against culture-confirmed
influenza was 94% for participants who received 2 doses of
LAIV separated by >6 weeks, and 89% for those who received
1 dose. In season two, when the A (H3N2) component in the
vaccine was not well-matched with circulating virus strains,
efficacy was 86%, for an overall efficacy over two influenza
seasons of 92%. Receipt of LAIV also resulted in 21% fewer
febrile illnesses and a significant decrease in acute otitis media
requiring antibiotics (233,235). Another randomized, placebo-
controlled trial demonstrated 85%–89% efficacy against
culture-confirmed influenza among children aged 6–35
months attending child care centers during consecutive influ-
enza seasons (236). In one community-based, nonrandomized
open-label study, reductions in MAARI were observed among
children who received 1 dose of LAIV during the 1990–00
and 2000–01 influenza seasons even though heterotypic vari-
ant influenza A/H1N1 and B were circulating during that
season (237).
Healthy Adults
A randomized, double-blind, placebo-controlled trial of
LAIV effectiveness among 4,561 healthy working adults aged
18–64 years assessed multiple endpoints, including reductions
in self-reported respiratory tract illness without laboratory
confirmation, work loss, health-care visits, and medication
use during influenza outbreak periods (238). The study was
conducted during the 1997–98 influenza season, when the
vaccine and circulating A (H3N2) strains were not well-
matched. The frequency of febrile illnesses was not signifi-
cantly decreased among LAIV recipients compared with those
who received placebo. However, vaccine recipients had sig-
nificantly fewer severe febrile illnesses (19% reduction) and
febrile upper respiratory tract illnesses (24% reduction), as
well as significant reductions in days of illness, days of work
lost, days with health-care–provider visits, and use of prescrip-
tion antibiotics and over-the-counter medications (238).
Efficacy against laboratory-confirmed influenza in a random-
ized, placebo-controlled study was 49%, although efficacy in
this study was not demonstrated to be significantly greater
than placebo (135).
Adverse Events after Receipt of LAIV
Children
In a subset of healthy children aged 60–71 months from
one clinical trial (233), certain signs and symptoms were
reported more often after the first dose among LAIV recipi-
ents (n = 214) than among placebo recipients (n = 95),
including runny nose (48% and 44%, respectively); headache
(18% and 12%, respectively); vomiting (5% and 3%, respec-
tively); and myalgias (6% and 4%, respectively). However,
these differences were not statistically significant. In other tri-
als, signs and symptoms reported after LAIV administration
have included runny nose or nasal congestion (20%–75%),
headache (2%–46%), fever (0%–26%), vomiting (3%–13%),
abdominal pain (2%), and myalgias (0%–21%)
(94,226,229,231,236,238–241). These symptoms were asso-
ciated more often with the first dose and were self-limited.
Data from a study including subjects aged 1–17 years indi-
cated an increase in asthma or reactive airways disease among
children aged 18–35 months (241). In another study, medi-
cally significant wheezing was more common within 42 days
after the first dose of LAIV (3.2%) compared with TIV (2.0%)
among previously unvaccinated children aged 6–23 months,
and hospitalization for any cause within 180 days of vaccina-
tion was significantly more common among LAIV (6.1%)
recipients aged 6 months–11 months compared with TIV
recipients (2.6%) (242). Another study was conducted among
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>11,000 children aged 18 months–18 years in which 18,780
doses of vaccine were administered for 4 years. For children
aged 18 months–4 years, no increase was reported in asthma
visits 0–15 days after vaccination compared with the
prevaccination period. A significant increase in asthma events
was reported 15–42 days after vaccination, but only in vac-
cine year 1 (243).
Adults
Among adults, runny nose or nasal congestion (28%–78%),
headache (16%–44%), and sore throat (15%–27%) have been
reported more often among vaccine recipients than placebo
recipients (218,244). In one clinical trial among a subset of
healthy adults aged 18–49 years, signs and symptoms reported
more frequently among LAIV recipients (n = 2,548) than pla-
cebo recipients (n = 1,290) within 7 days after each dose
included cough (14% and 11%, respectively); runny nose
(45% and 27%, respectively); sore throat (28% and 17%,
respectively); chills (9% and 6%, respectively); and tiredness/
weakness (26% and 22%, respectively) (244).
Persons at Higher Risk from Influenza-
Related Complications
LAIV is currently licensed for use only among healthy non-
pregnant persons aged 5–49 years. However, data assessing
the safety of LAIV use for certain groups at risk for influenza-
related complications are available. Studies conducted among
children aged 6–71 months with a history of recurrent respi-
ratory infections and among children aged 6–17 years with
asthma have not demonstrated differences in postvaccination
wheezing or asthma exacerbations, respectively (245,246). In
one study of 54 HIV-infected persons aged 18–58 years and
with CD4 counts >200 cells/mm3 who received LAIV, no
serious adverse events were reported during a 1-month follow-
up period (222). Similarly, one study demonstrated no sig-
nificant difference in the frequency of adverse events or viral
shedding among HIV-infected children aged 1–8 years on
effective antiretroviral therapy who were administered LAIV,
compared with HIV-uninfected children receiving LAIV
(223). LAIV was well-tolerated among adults aged >65 years
with chronic medical conditions (247). These findings sug-
gest that persons at risk for influenza complications who have
inadvertent exposure to LAIV would not have significant
adverse events or prolonged viral shedding and that persons
who have contact with persons at higher risk for influenza-
related complications may receive LAIV.
Serious Adverse Events
Serious adverse events requiring medical attention among
healthy children aged 5–17 years or healthy adults aged
18–49 years occurred at a rate of <1% (218). Surveillance will
continue for adverse events, including those that might not
have been detected in previous studies. Reviews of reports to
VAERS after vaccination of approximately 2.5 million per-
sons during the 2003–04 and 2004–05 influenza seasons did
not indicate any new safety concerns (248). Health-care pro-
fessionals should report all clinically significant adverse events
promptly to VAERS after LAIV administration.
Comparisons of LAIV and TIV Efficacy
Both TIV and LAIV have been demonstrated to be effec-
tive in children and adults, but data directly comparing the
efficacy or effectiveness of these two types of influenza vac-
cines are limited. Studies comparing the efficacy of TIV to
that of LAIV have been conducted in a variety of settings and
populations using several different clinical endpoints. One
randomized, double-blind, placebo-controlled challenge study
among 92 healthy adults aged 18–41 years assessed the effi-
cacy of both LAIV and TIV in preventing influenza infection
when challenged with wild-type strains that were antigeni-
cally similar to vaccine strains (249). The overall efficacy in
preventing laboratory-documented influenza from all three
influenza strains combined was 85% and 71%, respectively,
when challenged 28 days after vaccination by viruses to which
study participants were susceptible before vaccination. The
difference in efficacy between the two vaccines was not statis-
tically significant in this limited study, but efficacy at
timepoints later than 28 days after vaccination was not deter-
mined. In a randomized, double-blind, placebo-controlled
trial, conducted among young adults during an influenza sea-
son when the majority of circulating H3N2 viruses were anti-
genically drifted from that season’s vaccine viruses, the efficacy
of LAIV and TIV against culture-confirmed influenza was
57% and 77%, respectively. The difference in efficacy was
not statistically significant and was based largely upon a dif-
ference in efficacy against influenza B (135).
Although LAIV is not currently licensed for use in children
aged <5 years or in persons with risk factors for influenza com-
plications, several studies have compared the efficacy of LAIV
to TIV in these groups. LAIV provided 32% increased pro-
tection in preventing culture-confirmed influenza compared
with TIV in one study conducted among children aged
>6 years and adolescents with asthma (245) and 52%
increased protection among children aged 6–71 months with
recurrent respiratory tract infections (245). Another study
conducted among children aged 6–71 months during 2004–
2005 demonstrated a 55% reduction in cases of culture-
confirmed influenza among children who received LAIV
compared with those who received TIV (242).
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Effectiveness of Vaccination for
Decreasing Transmission to Contacts
Decreasing transmission of influenza from caregivers and
household contacts to persons at high risk might reduce
influenza-related deaths among persons at high risk.
Influenza virus infection and ILI are common among HCP
(250–252). Influenza outbreaks have been attributed to low
vaccination rates among HCP in hospitals and long-term–
care facilities (253–255). One serosurvey demonstrated that
23% of HCP had serologic evidence of influenza virus infec-
tion during a single influenza season; the majority had mild
illness or subclinical infection (250). Observational studies
have demonstrated that vaccination of HCP is associated with
decreased deaths among nursing home patients (256,257). In
one randomized controlled trial that included 2,604 residents
of 44 nursing homes, significant decreases were determined
in mortality, ILI, and medical visits for ILI care among resi-
dents in nursing homes in which staff were offered influenza
vaccination (coverage rate: 48%), compared with nursing
homes in which staff were not provided with vaccination (cov-
erage rate: 6%) (258). A recent review concluded that vaccina-
tion of HCP in settings in which patients were also vaccinated
provided significant reductions in deaths among elderly
patients from all causes and deaths from pneumonia (259).
Results from several recent studies have indicated that the
benefits of vaccinating children might extend to protection of
their adult contacts and to persons at risk for influenza com-
plications in the community, including persons at risk for
influenza complications. A single-blinded, randomized con-
trolled study conducted during 1996–1997 trial demonstrated
that vaccinating preschool-aged children with TIV reduced
influenza-related morbidity among their household contacts
(260). A community-based observational study conducted
during the 1968 pandemic using a univalent inactivated vac-
cine reported that a vaccination program targeting school-
aged children (coverage rate: 86%) in one community reduced
influenza rates within the community among all age groups
compared with another community in which aggressive vac-
cination was not conducted among school-aged children (261).
An observational study conducted in Russia demonstrated
reductions in ILI among the community-dwelling elderly
after implementation of a vaccination program using TIV for
children aged 3–6 years (57% coverage achieved) and chil-
dren and adolescents aged 7–17 years (72% coverage achieved)
(262). A randomized, placebo-controlled trial among children
with recurrent respiratory tract infections demonstrated that
members of families with children who had received LAIV
were significantly less likely to have respiratory tract infec-
tions and reported significantly fewer workdays lost, compared
with families with children who received placebo (263). In
nonrandomized community-based studies, administration of
LAIV has been demonstrated to reduce MAARI (264,265)
and ILI-related economic and medical consequences (e.g.,
workdays lost and number of health-care provider visits)
among contacts of vaccine recipients (265). Households with
children attending schools in which school-based LAIV
immunization programs had been established reported less
ILI and fewer physician visits during peak influenza season,
compared with households with children in schools in which
no LAIV immunization had been offered. However a decrease
in the overall rate of school absenteeism was not reported in
communities in which LAIV immunization was offered (265).
Cost-Effectiveness of Influenza
Vaccination
Influenza vaccination can reduce both health-care costs and
productivity losses associated with influenza illness. Studies
of influenza vaccination of persons aged >65 years conducted
in the United States have reported substantial reductions in
hospitalizations and deaths and overall societal cost savings
(159,160,266). Studies of adults aged <65 years have reported
that vaccination can reduce both direct medical costs and
indirect costs from work absenteeism (129,130,132–134,267).
Influenza vaccination has been estimated to decrease costs
associated with influenza illness, including 13%–44% reduc-
tions in health-care–provider visits, 18%–45% reductions in
lost workdays, 18%–28% reductions in days working with
reduced effectiveness, and 25% reductions in antibiotic use
for influenza-associated illnesses (129,131,268,269). One
analysis estimated a cost of approximately $4,500 per illness
averted among healthy persons aged 18–64 years in a typical
season, with cost/case averted decreasing to as low as $60 when
the influenza attack rate and vaccine effectiveness against ILI
are high (130). Another cost-benefit analysis that also included
costs from lost work productivity estimated an average
annual savings of $13.66 per person vaccinated (270).
Economic studies specifically evaluating the cost-
effectiveness of vaccinating persons in other age groups cur-
rently recommended for vaccination (e.g., persons aged 50–64
years or children aged 6–59 months) are limited and typically
demonstrate much higher costs in these healthier populations
(266,271–274). In a study of inactivated vaccine that included
persons in all age groups, cost utility (i.e., cost per year of
healthy life gained) improved with increasing age and among
those with chronic medical conditions (266). Among persons
aged >65 years, vaccination resulted in a net savings per qual-
ity-adjusted life year (QALY) saved. Another study estimated
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the cost-effectiveness of influenza vaccination to be $28,000
per QALY saved (in 2000 dollars) in persons aged 50–64 years
compared with $980 per QALY saved among persons aged
>65 years (275).
Cost analyses have documented the considerable cost bur-
den of illness among children. In a study of 727 children at a
single medical center during 2000–2004, the mean total cost
of hospitalization for influenza-related illness was $13,159
($39,792 for patients admitted to an intensive care unit and
$7,030 for patients cared for exclusively on the wards) (276).
Strategies that focus on vaccinating children with medical
conditions that confer a higher risk for influenza complica-
tions appear to be more cost-effective than a strategy of vacci-
nating all children (277). An analysis that compared the costs
of vaccinating children of varying ages with TIV and LAIV
determined that costs per QALY saved increased with age for
both vaccines. In 2003 dollars per QALY saved, costs for rou-
tine vaccination using TIV were $12,000 for healthy children
aged 6–23 months and $119,000 for healthy adolescents aged
12–17 years, compared with $9,000 and $109,000 using
LAIV, respectively (278).
Vaccination Coverage Levels
Continued annual monitoring is needed to determine the
effects on vaccination coverage of vaccine supply delays and
shortages, changes in influenza vaccination recommendations
and target groups for vaccination, reimbursement rates for
vaccine and vaccine administration, and other factors related
to vaccination coverage among adults and children. National
health objectives for 2010 include achieving an influenza vac-
cination coverage level of 90% for persons aged >65 years and
among nursing home residents (279,280), but new strategies
to improve coverage are needed to achieve these objectives
(281–282). Increasing vaccination coverage among persons
who have high-risk conditions and are aged <65 years, in-
cluding children at high risk, is the highest priority for ex-
panding influenza vaccine use.
On the basis of preliminary data from the National Health
Interview Survey (NHIS), estimated national influenza vac-
cine coverage in the second quarter of 2006 among persons
aged >65 years and 50–64 years was 66% and 32%, respec-
tively (283). Compared with coverage estimates from the 2005
NHIS, coverage in these age groups has increased (Table 5)
(283). In early October 2004, one of the influenza vaccine
manufacturers licensed in the United States announced that
it would be unable to supply any vaccine to the United States,
causing an abrupt and substantial decline in vaccine availabil-
ity and prompting ACIP to recommend that vaccination ef-
forts target certain groups at higher risk for influenza
complications. The inability of this manufacturer to produce
vaccine for the United States reduced by almost one half the
expected supply of TIV available for the 2004–05 influenza
season (284,285). Although vaccine supply was adequate for
the 2005–06 influenza season, recent trends in vaccination
coverage are difficult to interpret until analyses of recent NHIS
vaccination coverage data are completed.
During 1989–1999, influenza vaccination levels among
persons aged >65 years increased from 33% to 66% (286,287),
surpassing the Healthy People 2000 objective of 60% (281).
Possible reasons for increases in influenza vaccination levels
among persons aged >65 years include 1) greater acceptance
of preventive medical services by practitioners; 2) increased
delivery and administration of vaccine by health-care provid-
ers and sources other than physicians; 3) new information
regarding influenza vaccine effectiveness, cost-effectiveness,
and safety; and 4) initiation of Medicare reimbursement for
influenza vaccination in 1993 (129,160,166,167,288,289).
However, since 1997, increases in influenza vaccination cov-
erage levels among the elderly have slowed markedly, with
coverage estimates during years without vaccine shortages since
1997 ranging between 63% and 66%.
In 2004, estimated vaccination coverage levels among adults
with high-risk conditions aged 18–49 years and 50–64 years
were 26% and 46%, respectively, substantially lower than the
Healthy People 2000 and Healthy People 2010 objectives of
60% (Table 5) (279,280). In 2005, vaccination coverage
among persons in these groups decreased to 18% and 34%,
respectively; vaccine shortages during the previous influenza
season likely contributed to these declines in coverage.
Opportunities to vaccinate persons at risk for influenza com-
plications (e.g., during hospitalizations for other causes)
often are missed. In a study of hospitalized Medicare patients,
only 31.6% were vaccinated before admission, 1.9% during
admission, and 10.6% after admission (290). A study con-
ducted in New York City during 2001–2005 among 7,063
children aged 6–23 months determined that 2-dose vaccine
coverage increased from 1.6% to 23.7%. Although the aver-
age number of medical visits during which an opportunity to
be vaccinated decreased during the course of the study from
2.9 to 2.0 per child, 55% of all visits during the final year of
the study still represented a missed vaccination opportunity
(291). Using standing orders in hospitals increases vaccina-
tion rates among hospitalized persons (292). In one survey,
the strongest predictor of receiving vaccination was the sur-
vey respondent’s belief that he or she was in a high-risk group.
However, many persons in high-risk groups did not know
that they were in a group recommended for vaccination (293).
Reducing racial and ethnic health disparities, including dis-
parities in influenza vaccination coverage, is an overarching
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national goal that is not being met (279). Although estimated
influenza vaccination coverage for the 1999–00 season reached
the highest levels recorded among older black, Hispanic, and
white populations, vaccination levels among blacks and His-
panics continue to lag behind those among whites (287,294).
Estimated vaccination coverage levels in 2005 among persons
aged >65 years were 68% for non-Hispanic whites, 47% for
non-Hispanic blacks, and 49% for Hispanics (283). Among
Medicare beneficiaries, unequal access to care might not be
the only factor in contributing toward disparity levels; other
key factors include having patients that actively seek vaccina-
tion and providers that recommend vaccination (295,296).
One study estimated that eliminating these disparities in vac-
cination coverage would have an impact on mortality similar
to the impact of eliminating deaths attributable to kidney dis-
ease among blacks or liver disease among Hispanics (297).
Reported vaccination levels are low among children at
increased risk for influenza complications. Coverage among
children aged 2–17 years with asthma for the 2004–05 influ-
enza season was estimated to be 29% (298). One study
reported 79% vaccination coverage among children attend-
ing a cystic fibrosis treatment center (299). During the first
season for which ACIP recommended that all children aged 6
months–23 months receive vaccination, 33% received >1 dose
of influenza vaccination, and 18% received 2 doses if they
were unvaccinated previously (300). Among children enrolled
in HMOs who had received a first dose during 2001–2004,
second dose coverage varied from 29% to 44% among chil-
dren aged 6–23 months and from 12% to 24% among chil-
dren aged 2–8 years (301). A rapid analysis of influenza
vaccination coverage levels among members of an HMO in
Northern California demonstrated that during 2004–2005,
TABLE 5. Influenza vaccination* coverage levels among population groups — National Health Interview Survey (NHIS) and National
Immunization Survey (NIS), United States, 2005
Influenza vaccination level
Population group Crude sample size† %    (95% CI§)
Persons with an age indication
Aged 6–23 mos (NIS¶) 12,056 33.4 (32.0–34.8)
Aged 50–64 yrs 7,241 22.9 (21.9–24.0)
Aged >65 yrs 5,944 59.6 (58.0–61.0)
Persons with high-risk conditions**
Aged 2–17 yrs 985 28.4 (25.3–31.8)
Aged 18–49 yrs 2,576 18.0 (16.3–19.7)
Aged 50–64 yrs 2,350 34.2 (32.0–36.4)
Aged 18–64 yrs 4,926 25.3 (24.0–26.7)
Persons without high-risk conditions¶
Aged 2–17 yrs 8,631 12.6 (11.7–13.6)
Aged 18–49 yrs 14,970 9.5 (8.9–10.0)
Aged 50–64 yrs 4,880 17.8 (16.6–19.1)
Pregnant women†† 304 15.6 (11.2–21.2)
Health-care personnel (HCP)§§ 2,135 33.5 (31.5–35.7)
Household contacts of persons at high risk, including children aged <2 years¶¶
Aged 2–17 yrs 2,150 16.6 (14.7–18.7)
Aged 18–49 yrs 2,331 8.9 (7.7–10.3)
* Answered yes to this question, “During the past 12 months, have you had a flu shot (flu spray),” during a face-to-face interview conducted any day during 2005.
† Population sizes by subgroups are listed at http://www.cdc.gov/flu/professionals/vaccination/pdf/targetpopchart.pdf.
§ Confidence interval.
¶ NIS uses provider-verified vaccination status to improve the accuracy of the estimate.
** Adults categorized as being at high risk for influenza-related complications self-reported one or more of the following: 1) ever being told by a physician they
had diabetes, emphysema, coronary heart disease, angina, heart attack, or other heart condition; 2) having a diagnosis of cancer during the previous 12
months (excluding nonmelanoma skin cancer) or ever being told by a physician they have lymphoma, leukemia, or blood cancer during the previous 12
months; 3) being told by a physician they have chronic bronchitis or weak or failing kidneys; or 4) reporting an asthma episode or attack during the
preceding 12 months. For children aged <18 years, high-risk conditions included ever having been told by a physician of having diabetes, cystic fibrosis,
sickle cell anemia, congenital heart disease, other heart disease, or neuromuscular conditions (seizures, cerebral palsy, and muscular dystrophy), or
having an asthma episode or attack during the preceding 12 months.
†† Aged 18–44 years, pregnant at the time of the survey, and without high-risk conditions.
§§ Adults were classified as HCP if they were currently employed in a health-care occupation or in a health-care–industry setting, on the basis of recoded
broad groups of standard occupation and industry categories.
¶¶ Interviewed adult or sample child in each household containing at least one of the following: a child aged <2 years, an adult aged >65 years, or any person
aged 5–17 years at high risk (see previous ** footnote). To obtain information on household composition and high-risk status of household members, the
sampled adult, child, and person files from NHIS were merged. Interviewed adults who were HCP or who had high-risk conditions and sample children with
high-risk conditions were excluded. Information could not be assessed regarding high-risk status of other adults aged 18–64 years or children aged 2–17
years in the household; thus, certain persons aged 2–64 years who lived with a person aged 2–64 years at high risk were not included in the analysis.
22 MMWR July 13, 2007
the first year of the recommendation for vaccination of chil-
dren aged 6–23 months, 1-dose coverage was 57% (302). Data
collected in February 2005 indicated a national estimate of
48% vaccination coverage for >1 doses among children aged
6–23 months and 35% coverage among children aged 2–17
years who had one or more high-risk medical conditions dur-
ing the 2004–05 season (303). As has been reported for older
adults, a physician recommendation for vaccination and the
perception that having a child be vaccinated “is a smart idea”
were associated positively with likelihood of vaccination of
children aged 6–23 months (304). Similarly, children with
asthma were more likely to be vaccinated if their parents
recalled a physician recommendation to be vaccinated or
believed that the vaccine worked well (305). Implementation
of a reminder/recall system in a pediatric clinic increased the
percentage of children with asthma or reactive airways disease
receiving vaccination from 5% to 32% (306).
Although annual vaccination is recommended for HCP and
is a high priority for reducing morbidity associated with
influenza in health-care settings and for expanding influenza
vaccine use (307–309), national survey data demonstrated a
vaccination coverage level of only 42% among HCP (CDC,
unpublished data, 2006). Vaccination of HCP has been asso-
ciated with reduced work absenteeism (251) and with fewer
deaths among nursing home patients (257,258) and elderly
hospitalized patients (260). Factors associated with a higher
rate of influenza vaccination among HCP include older age,
being a hospital employee, having employer provided health-
care insurance, having had pneumococcal or hepatitis B vac-
cination in the past, or having visited a health-care professional
during the previous year. Non-Hispanic black HCP were less
likely than non-Hispanic white HCP to be vaccinated (310).
Limited information is available regarding influenza vac-
cine coverage among pregnant women. In a national survey
conducted during 2001 among women aged 18–44 years with-
out diabetes, those who were pregnant were significantly less
likely to report influenza vaccination during the previous 12
months (13.7%) than those women who were not pregnant
(16.8%) (311). Only 16% of pregnant women participating
in the 2005 NHIS reported vaccination, excluding pregnant
women who reported diabetes, heart disease, lung disease, and
other selected high-risk conditions (CDC, unpublished data,
2006) (Table 5). In a study of influenza vaccine acceptance by
pregnant women, 71% of those who were offered the vaccine
chose to be vaccinated (312). However, a 1999 survey of
obstetricians and gynecologists determined that only 39%
administered influenza vaccine to obstetric patients in their
practices, although 86% agreed that pregnant women’s risk
for influenza-related morbidity and mortality increases dur-
ing the last two trimesters (313).
Data indicate that self-report of influenza vaccination among
adults, compared with determining vaccination status from
the medical record, is both a sensitive and specific source of
information (314). Patient self-reports should be accepted as
evidence of influenza vaccination in clinical practice (314).
However, information on the validity of parents’ reports of
pediatric influenza vaccination is not yet available.
Recommendations for Using TIV
and LAIV During the 2007–08
Influenza Season
Both TIV and LAIV prepared for the 2007–08 season will
include A/Solomon Islands/3/2006 (H1N1)-like, A/Wisconsin/
67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like anti-
gens. These viruses will be used because they are representa-
tive of influenza viruses that are anticipated to circulate in the
United States during the 2007–08 influenza season and have
favorable growth properties in eggs.
TIV and LAIV can be used to reduce the risk for influenza
virus infection and its complications. Immunization provid-
ers should administer influenza vaccine to any person who
wishes to reduce the likelihood of becoming ill with influenza
or transmitting influenza to others should they become
infected. Healthy, nonpregnant persons aged 5–49 years can
choose to receive either vaccine.
TIV is FDA-approved for persons aged >6 months, includ-
ing those with high-risk conditions, whereas LAIV is FDA-
approved for use only among healthy persons aged 5–49 years.
All children aged >6 months–8 years who have not been vac-
cinated previously at any time with either LAIV or TIV should
receive 2 doses of age-appropriate vaccine in the same season,
with a single dose during subsequent seasons.
Target Groups for Vaccination
All persons at risk for medical complications from influ-
enza or more likely to require medical care and all persons
who live with or care for persons at high risk for influenza-
related complications should receive influenza vaccine annu-
ally. Approximately 73% of the United States population is
included in one or more of these target groups; however, only
an estimated one third of the United States population
received an influenza vaccination in 2006–2007. When vac-
cine supply is limited, vaccination efforts should focus on
delivering vaccination to these persons.
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Persons at Risk for Medical Complications
or More Likely to Require Medical Care
Vaccination with TIV is recommended for the following
persons who are at increased risk for severe complications from
influenza, or at higher risk for influenza-associated clinic,
emergency department, or hospital visits:
• all children aged 6–59 months (i.e., 6 months–4 years;
• all persons aged >50 years;
• children and adolescents (aged 6 months–18 years) who
are receiving long-term aspirin therapy and who there-
fore might be at risk for experiencing Reye syndrome
after influenza virus infection;
• women who will be pregnant during the influenza season;
• adults and children who have chronic pulmonary (includ-
ing asthma), cardiovascular (except hypertension), renal,
hepatic, hematological or metabolic disorders (including
diabetes mellitus);
• adults and children who have immunosuppression
(including immunosuppression caused by medications or
by HIV);
• adults and children who have any condition (e.g., cogni-
tive dysfunction, spinal cord injuries, seizure disorders,
or other neuromuscular disorders) that can compromise
respiratory function or the handling of respiratory secre-
tions or that can increase the risk for aspiration; and
• residents of nursing homes and other chronic-care facilities.
Persons Who Live With or Care for Persons at
High Risk for Influenza-Related Complications
To prevent transmission to persons identified above, vacci-
nation with TIV or LAIV (unless contraindicated) also is rec-
ommended for the following persons:
• HCP;
• healthy household contacts (including children) and
caregivers of children aged <59 months (i.e., aged <5 years)
and adults aged >50 years; and
• healthy household contacts (including children) and
caregivers of persons with medical conditions that put
them at higher risk for severe complications from
influenza.
Additional Information Regarding
Vaccination of Specific Populations
Children
Any child aged >6 months may be vaccinated. However,
vaccination is specifically recommended for certain children,
including all children aged 6–59 months, children with cer-
tain medical conditions, and children who are contacts of
persons at higher risk for influenza complications. The Ameri-
can Academy of Pediatrics (AAP) has developed an algorithm
for determining specific recommendations for pediatric
patients according to age, contact or health status has been
provided (Figure).
Because children aged 6–23 months are at substantially
increased risk for influenza-related hospitalizations, and chil-
dren aged 24–59 months (i.e., 2–4 years) are at increased risk
for influenza-related clinic and emergency department visits
(34), ACIP recommends that all children aged 6 months–
4 years receive TIV. Influenza vaccines are not approved by
FDA for use among children aged <6 months.
All children aged 6 months–8 years who have not received
vaccination against influenza previously should receive 2 doses
of vaccine the first year they are vaccinated. Children aged
5–8 years who receive TIV should have a booster dose of TIV
administered >1 month after the initial dose, ifpossible before
the onset of influenza season. LAIV is not currently licensed
for children aged <5 years. Children aged 5–8 years who
receive LAIV should have a second dose of LAIV 6 or more
weeks after the initial dose. If possible, both doses should be
administered before onset of influenza season. However, vac-
cination, including the second dose, is recommended even
after influenza virus begins to circulate in a community.
Although data are limited, recently published studies indi-
cate that when young children receive only 1 dose of TIV in
each of their first two seasons of being vaccinated, they have
lower antibody levels, are less likely to have protective anti-
body titers (110), and have reduced protection against ILI
compared with children who receive their first 2 doses of vac-
cine in the same season (116). ACIP recommends 2 vaccine
doses for children aged 6 months–8 years who received an
influenza vaccine (either TIV or LAIV) for the first time in
the previous season but who did not receive the recommended
second dose of vaccine within the same season. ACIP recom-
mendations are now harmonized with regard to this issue with
those of AAP (315). This recommendation represents a change
from the 2006 recommendations, in which children aged
6 months–8 years who received only 1 dose of vaccine in their
first year of vaccination were recommended to receive only a
single dose in the following season. ACIP does not recom-
mend that a child receive influenza vaccine for the first time
in the spring with the intent of providing a priming dose for
the following season. Children recommended for vaccination
who are in their third or more year of being vaccinated and
who received only 1 dose in each of their first 2 years of being
vaccinated should continue receiving a single annual dose.
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How many doses of influenza
vaccine has the patient
received this season?
Influenza vaccination is not
currently recommended at this
time for this patient.
Vaccination is recommended
for household or caregiver
contacts of children who are
recommended for vaccination
on the basis of age or medical
conditions, particularly for
contacts of children aged <6
months. For children who are
recommended to receive a
second vaccine dose, a later
visit should be scheduled.
Is the patient aged
6 months?> No
Yes






Was the patient aged
9 years at the time






Did the patient receive
2 influenza vaccine doses
in the initial season?
Is it the first or second
influenza season in
which the patient will
be vaccinated?
No
What type of vaccine




Has 4 weeks elapsed
since the first dose?TIV
†
Yes
Has 6 weeks elapsed









Does the patient have any
high-risk conditions?No
Is the patient a household
contact of a child aged
<5 years or of anyone with
a high-risk condition, or has






Administer first dose of influenza vaccine. (See Tables 2 and 4 for product
descriptions, comparisons, and approved vaccinations for different age groups.)
Vaccination is recommended for household or caregiver contacts of children who are
recommended for vaccination on the basis of age or medical conditions, particularly
for contacts of children aged <6 months.









FIGURE. Algorithm for determining recommended influenza immunization actions for children*
* Source: Modified with permission from the American Academy of Pediatrics’ Committee on Infectious Diseases. Prevention of influenza: recommendations
for influenza immunization of children, 2006–2007. Pediatrics 2007;119:846–51.315.
†Trivalent inactivated influenza vaccine.
§Live, attenuated influenza vaccine.
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Persons Aged 50–64 Years
Vaccination is recommended for all persons aged 50–64 years
because persons in this age group have an increased preva-
lence of high-risk conditions and low vaccination rates. In
2002, approximately 43.6 million persons in the United States
were aged 50–64 years, of whom 13.5 million (34%) had one
or more high-risk medical conditions (316). Persons aged
50–64 years without high-risk conditions also benefit from
vaccination in the form of decreased rates of influenza illness,
work absenteeism, and need for medical visits and medica-
tions, including antibiotics (128,129,131,132). In addition,
other preventive services and routine assessment of vaccina-
tion and other preventive services has been recommended for
all persons aged >50 years (317,318).
HCP and Other Persons Who Can
Transmit Influenza to Those at High
Risk
Healthy persons who are clinically or asymptomatically
infected can transmit influenza virus to persons at higher risk
for complications from influenza. In addition to HCP, groups
that can transmit influenza to high-risk persons and that should
be vaccinated include
• employees of assisted living and other residences for per-
sons in groups at high risk;
• persons who provide home care to persons in groups at
high risk; and
• household contacts (including children) of persons in
groups at high risk.
In addition, because children aged <5 years are at increased
risk for influenza-related hospitalization (2,33,55,57) com-
pared with older children, vaccination is recommended for
their household contacts and out-of-home caregivers. Because
influenza vaccines have not been approved by FDA for use
among children aged <6 months, emphasis should be placed
on vaccinating contacts of children aged <6 months. When
vaccine supply is limited, priority for vaccination should be
given to contacts of children aged <6 months.
Healthy persons aged 5–49 years in these groups who are
not contacts of severely immunosuppressed persons (see Vac-
cination of Close Contacts of Immunocompromised Persons)
may receive either LAIV or TIV. All other persons should
receive TIV.
All HCP, as well as those in training for health-care profes-
sions, should be vaccinated annually against influenza. Per-
sons working in health-care settings who should be vaccinated
include physicians, nurses, and other workers in both hospi-
tal and outpatient-care settings, medical emergency-response
workers (e.g., paramedics and emergency medical technicians),
employees of nursing home and chronic-care facilities who
have contact with patients or residents, and students in these
professions who will have contact with patients (308,309,319).
Facilities that employ HCP should provide vaccine to work-
ers by using approaches that have been demonstrated to be
effective in increasing vaccination coverage. Health-care
administrators should consider the level of vaccination cover-
age among HCP to be one measure of a patient safety quality
program and obtain signed declinations from personnel who
decline influenza vaccination for reasons other than medical
contraindications (309). Influenza vaccination rates among
HCP within facilities should be regularly measured and
reported, and ward-, unit-, and specialty-specific coverage rates
should be provided to staff and administration (309). Studies
have demonstrated that organized campaigns can attain higher
rates of vaccination among HCP with moderate effort and
using strategies that increase vaccine acceptance (307,309,320).
Efforts to increase vaccination coverage among HCP are
supported by various national accrediting and professional
organizations and in certain states by statute. The Joint Com-
mission on Accreditation of Health-Care Organizations has
approved an infection control standard that requires accred-
ited organizations to offer influenza vaccinations to staff,
including volunteers and licensed independent practitioners
with close patient contact. The standard became an accredita-
tion requirement beginning January 1, 2007 (321). In addi-
tion, the Infectious Diseases Society of America recently
recommended mandatory vaccination for HCP, with a provi-
sion for declination of vaccination based on religious or medical
reasons (322). Fifteen states have regulations regarding vacci-
nation of HCP in long-term–care facilities (323), three states
require that health-care facilities offer influenza vaccination
to HCP, and three states require that HCP either receive
influenza vaccination or indicate a religious, medical, or philo-
sophical reason for not being vaccinated (324).
Vaccination of Close Contacts
of Immunocompromised Persons
Immunocompromised persons are at risk for influenza com-
plications but might have insufficient responses to vaccina-
tion. Close contacts of immunocompromised persons,
including HCP, should be vaccinated to reduce the risk for
influenza transmission. TIV is preferred for vaccinating house-
hold members, HCP, and others who have close contact with
severely immunosuppressed persons (e.g., patients with
hematopoietic stem cell transplants) during those periods in
which the immunosuppressed person requires care in a pro-
tective environment (typically defined as a specialized patient-
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care area with a positive airflow relative to the corridor, high-
efficiency particulate air filtration, and frequent air changes)
(325).
LAIV transmission from a recently vaccinated person caus-
ing clinically important illness in an immunocompromised
contact has not been reported. The rationale for avoiding use
of LAIV among HCP caring for such patients is the
theoretic risk that a live, attenuated vaccine virus could be
transmitted to the severely immunosuppressed person. As a
precautionary measure, HCP who receive LAIV should avoid
providing care for severely immunosuppressed patients for
7 days after vaccination. Hospital visitors who have received
LAIV should avoid contact with severely immunosuppressed
persons for 7 days after vaccination but should not be restricted
from visiting less severely immunosuppressed patients.
No preference is indicated for TIV use by persons who have
close contact with persons with lesser degrees of immunosup-
pression (e.g., persons with diabetes, persons with asthma who
take corticosteroids, those who might have been cared for pre-
viously in a protective environment but who are no longer in
that protective environment, or persons infected with HIV) or
for TIV use by HCP or other healthy persons aged 5–49 years
in close contact with persons in all other groups at high risk.
Pregnant Women
Pregnant women are at risk for influenza complications, and
all women who are pregnant or will be pregnant during influ-
enza season should be vaccinated. FDA has classified TIV as a
“Pregnancy Category C” medication, indicating that animal
reproduction studies have not been conducted. Whether
influenza vaccine can cause fetal harm when administered to
a pregnant woman or affect reproductive capacity is not
known. However, one study of approximately 2,000 pregnant
women who received TIV during pregnancy demonstrated
no adverse fetal effects and no adverse effects during infancy
or early childhood (326). A matched case-control study of
252 pregnant women who received TIV within the 6 months
before delivery determined no adverse events after vaccina-
tion among pregnant women and no difference in pregnancy
outcomes compared with 826 pregnant women who were not
vaccinated (152). During 2000–2003, an estimated 2 million
pregnant women were vaccinated, and only 20 adverse events
among women who received TIV were reported to VAERS
during this time, including nine injection-site reactions and
eight systemic reactions (e.g., fever, headache, and myalgias).
In addition, three miscarriages were reported, but these were
not known to be causally related to vaccination (327). Similar
results have been reported in several smaller studies
(151,153,328) The American College of Obstetricians and
Gynecologists and the American Academy of Family Physi-
cians also have recommended routine vaccination of all preg-
nant women (329). No preference is indicated for use of TIV
that does not contain thimerosal as a preservative (see Vaccine
Preservative [Thimerosal] in Multidose Vials of TIV) for any
group recommended for vaccination, including pregnant
women. LAIV is not licensed for use in pregnant women.
However, pregnant women do not need to avoid contact with
persons recently vaccinated with LAIV.
Breastfeeding Mothers
Vaccination is recommended for all persons, including
breastfeeding women, who are contacts of infants or children
aged <59 months (i.e., <5 years), because infants and young
children are at higher risk for influenza complications and are
more likely to require medical care or hospitalization if infected.
Breastfeeding does not affect the immune response adversely
and is not a contraindication for vaccination (171). Women
who are breastfeeding may receive either TIV or LAIV unless
contraindicated because of other medical conditions.
Travelers
The risk for exposure to influenza during travel depends on
the time of year and destination. In the temperate regions of
the Southern Hemisphere, influenza activity occurs typically
during April–September. In temperate climate zones of the
Northern and Southern Hemispheres, travelers also can be
exposed to influenza during the summer, especially when trav-
eling as part of large tourist groups (e.g., on cruise ships) that
include persons from areas of the world in which influenza
viruses are circulating (330,331). In the tropics, influenza
occurs throughout the year. In one recent study among Swiss
travelers to tropical and subtropical countries, influenza was
the most frequently acquired vaccine-preventable disease (332).
Any traveler who wants to reduce the risk for influenza
infection should consider influenza vaccination, preferably at
least 2 weeks before departure. In particular, persons at high
risk for complications of influenza and who were not vacci-
nated with influenza vaccine during the preceding fall or win-
ter should consider receiving influenza vaccine before travel if
they plan to
• travel to the tropics,
• travel with organized tourist groups at any time of year,
or
• travel to the Southern Hemisphere during April–September.
No information is available regarding the benefits of revac-
cinating persons before summer travel who already were vac-
cinated in the preceding fall. Persons at high risk who receive
the previous season’s vaccine before travel should be revacci-
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nated with the current vaccine the following fall or winter.
Persons at higher risk for influenza complications should con-
sult with their health-care practitioner to discuss the risk for
influenza or other travel-related diseases before embarking on
travel during the summer.
General Population
Vaccination is recommended for any person who wishes to
reduce the likelihood of becoming ill with influenza or trans-
mitting influenza to others should they become infected.
Healthy, nonpregnant persons aged 5–49 years may choose to
receive either TIV or LAIV. All other persons aged >6 months
should receive TIV. Persons who provide essential commu-
nity services should be considered for vaccination to mini-
mize disruption of essential activities during influenza
outbreaks. Students or other persons in institutional settings
(e.g., those who reside in dormitories or correctional facili-
ties) should be encouraged to receive vaccine to minimize
morbidity and the disruption of routine activities during
epidemics (333,334).
Recommended Vaccines for Different
Age Groups
When vaccinating children aged 6–35 months, health-care
providers should use TIV that has been approved by FDA for
this age group. TIV from Sanofi Pasteur (FluZone split-virus)
is approved for use among persons aged >6 months. TIV from
Novartis (Fluvirin) is FDA-approved in the United States for
use among persons aged >4 years. TIV from GlaxoSmithKline
(Fluarix and FluLaval) is labeled for use in persons aged >18
years, because data to demonstrate efficacy among younger
persons have not been provided to FDA. LAIV from
MedImmune (FluMist) is currently approved for use by healthy
nonpregnant persons aged 5–49 years (Table 4). Expanded
age and risk group indications for currently licensed vaccines
are likely over the next several years, and immunization pro-
viders should be alert to these changes. In addition, several
new vaccine formulations are being evaluated in immunoge-
nicity and efficacy trials; when licensed, these new products
will increase the influenza vaccine supply and provide addi-
tional vaccine choices for practitioners and their patients.
Influenza Vaccines and Use
of Influenza Antiviral Medications
Administration of TIV and influenza antivirals during the
same medical visit is acceptable. The effect on safety and effi-
cacy of LAIV coadministration with influenza antiviral medi-
cations has not been studied. However, because influenza
antivirals reduce replication of influenza viruses, LAIV should
not be administered until 48 hours after cessation of influ-
enza antiviral therapy, and influenza antiviral medications
should not be administered for 2 weeks after receipt of LAIV.
Persons receiving antivirals within the period 2 days before to
14 days after vaccination with LAIV should be revaccinated
at a later date (171,218).
Persons Who Should Not Be Vaccinated
with TIV
TIV should not be administered to persons known to have
anaphylactic hypersensitivity to eggs or to other components
of the influenza vaccine. Prophylactic use of antiviral agents is
an option for preventing influenza among such persons.
Information regarding vaccine components is located in pack-
age inserts from each manufacturer. Persons with moderate to
severe acute febrile illness usually should not be vaccinated
until their symptoms have abated. However, minor illnesses
with or without fever do not contraindicate use of influenza
vaccine. GBS within 6 weeks following a previous dose of
TIV is considered to be a precaution for use of TIV.
Considerations When Using LAIV
Currently, LAIV is an option for vaccination of healthy,
nonpregnant persons aged 5–49 years, including HCP and
other close contacts of high-risk persons. No preference is
indicated for LAIV or TIV when considering vaccination of
healthy, nonpregnant persons aged 5–49 years. However, dur-
ing periods when inactivated vaccine is in short supply, use of
LAIV is encouraged when feasible for eligible persons (includ-
ing HCP) because use of LAIV by these persons might
increase availability of TIV for persons in groups targeted for
vaccination, but who cannot receive LAIV. Possible advan-
tages of LAIV include its potential to induce a broad mucosal
and systemic immune response in children, its ease of admin-
istration, and the possibly increased acceptability of an intra-
nasal rather than intramuscular route of administration.
If the vaccine recipient sneezes after administration, the dose
should not be repeated. However, if nasal congestion is present
that might impede delivery of the vaccine to the nasopharyn-
geal mucosa, deferral of administration should be considered
until resolution of the illness, or TIV should be administered
instead. No data exist regarding concomitant use of nasal
cortosteroids or other intranasal medications (218).
LAIV should be administered annually according to the
following schedule:
• Children aged 5–8 years previously unvaccinated at any
time with either LAIV or TIV should receive 2 doses of
LAIV separated by at least 6 weeks.
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• Children aged 5–8 years previously vaccinated at any time
with either LAIV or TIV should receive 1 dose of LAIV.
However, a child of this age who received influenza vac-
cine for the first time in the previous season and did not
receive 2 doses in that season should receive 2 doses as
above during the current season.
• Persons aged 9–49 years should receive 1 dose of LAIV.
LAIV may be administered to persons with minor acute
illnesses (e.g., diarrhea or mild upper respiratory tract infec-
tion with or without fever). However, if nasal congestion is
present that might impede delivery of the vaccine to the
nasopharyngeal mucosa, deferral of administration should be
considered until resolution of the illness.
Whether concurrent administration of LAIV with other
vaccines affects the safety or efficacy of either LAIV or the
simultaneously administered vaccine is unknown. In the
absence of specific data indicating interference, following
ACIP’s general recommendations for immunization is pru-
dent (171). Inactivated vaccines do not interfere with the
immune response to other inactivated vaccines or to live vac-
cines. Inactivated or live vaccines may be administered simul-
taneously with LAIV. However, after administration of a live
vaccine, at least 4 weeks should pass before another live vac-
cine is administered.
Persons Who Should Not Be Vaccinated
with LAIV
LAIV is not currently licensed for use in the following
groups, and these persons should not be vaccinated with LAIV:
• persons with a history of hypersensitivity, including ana-
phylaxis, to any of the components of LAIV or to eggs.
• persons aged <5 years or those aged >50 years;
• persons with any of the underlying medical conditions
that serve as an indication for routine influenza vaccina-
tion, including asthma, reactive airways disease, or other
chronic disorders of the pulmonary or cardiovascular sys-
tems; other underlying medical conditions, including such
metabolic diseases as diabetes, renal dysfunction, and
hemoglobinopathies; or known or suspected immunode-
ficiency diseases or immunosuppressed states;
• children or adolescents receiving aspirin or other salicy-
lates (because of the association of Reye syndrome with
wild-type influenza virus infection);
• persons with a history of GBS; or
• pregnant women.
Personnel Who May Administer LAIV
Low-level introduction of vaccine viruses into the environ-
ment is likely unavoidable when administering LAIV. The risk
for acquiring vaccine viruses from the environment is unknown
but likely to be low. Severely immunosuppressed persons
should not administer LAIV. However, other persons at high
risk for influenza complications may administer LAIV. These
include persons with underlying medical conditions placing
them at high risk or who are likely to be at risk, including preg-




Although influenza vaccination levels increased substantially
during the 1990s, little progress has been made toward achiev-
ing national health objectives, and further improvements in
vaccine coverage levels are needed. Strategies to improve vac-
cination levels, including using reminder/recall systems and
standing orders programs (281–283,335,336), should be
implemented whenever feasible. Vaccination coverage can be
increased by administering vaccine before and during the
influenza season to persons during hospitalizations or routine
health-care visits. Immunizations can be provided in alterna-
tive settings (e.g., pharmacies, grocery stores, workplaces or
other locations in the community), thereby making special
visits to physicians’ offices or clinics unnecessary. Coordinated
campaigns such as the National Influenza Vaccination Week
(November 26–December 2, 2007) provide opportunities to
refocus public attention on the benefits, safety, and availabil-
ity of influenza vaccination throughout the influenza season.
When educating patients regarding potential adverse events,
clinicians should emphasize that 1) TIV contains noninfec-
tious killed viruses and cannot cause influenza, 2) LAIV con-
tains weakened influenza viruses that cannot replicate outside
the upper respiratory tract and are unlikely to infect others,
and 3) concomitant symptoms or respiratory disease unre-
lated to vaccination with either TIV or LAIV can occur after
vaccination.
Information About the Vaccines
for Children Program
The Vaccines for Children (VFC) program supplies vac-
cine to all states, territories, and the District of Columbia for
use by participating providers. These vaccines are to be pro-
vided to eligible children without vaccine cost to the patient
or the provider. All routine childhood vaccines recommended
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by ACIP are available through this program, including influ-
enza vaccines. The program saves parents and providers out-
of-pocket expenses for vaccine purchases and provides cost
savings to states through CDC’s vaccine contracts. The pro-
gram results in lower vaccine prices and ensures that all states
pay the same contract prices. Detailed information about the




The annual supply of influenza vaccine and the timing of
its distribution cannot be guaranteed in any year. During the
2006–07 influenza season, >100 million doses of influenza
vaccine were distributed in the United States. Total produc-
tion of influenza vaccine for the United States is anticipated
to be >100 million doses for the 2007–08 season, depending
on demand and production yields. However, influenza vac-
cine distribution delays or vaccine shortages remain possible
in part because of the inherent critical time constraints in
manufacturing the vaccine given the annual updating of the
influenza vaccine strains and various other manufacturing and
regulatory issues. To ensure optimal use of available doses of
influenza vaccine, health-care providers, those planning orga-
nized campaigns, and state and local public health agencies
should develop plans for expanding outreach and infrastruc-
ture to vaccinate more persons in targeted groups and others
who wish to reduce their risk for influenza and develop con-
tingency plans for the timing and prioritization of adminis-
tering influenza vaccine if the supply of vaccine is delayed or
reduced.
If supplies of TIV are not adequate, vaccination should be
carried out in accordance with local circumstances of supply
and demand based on the judgment of state and local health
officials and health-care providers. Guidance for tiered use of
TIV during prolonged distribution delays or supply shortfalls
is available at http://www.cdc.gov/flu/professionals/vaccina-
tion/vax_priority.htm and will be modified as needed in the
event of shortage. CDC and other public health agencies will
assess the vaccine supply on a continuing basis throughout
the manufacturing period and will inform both providers and
the general public if any indication exists of a substantial
delay or an inadequate supply.
Because LAIV is approved only for use in healthy persons
aged 5–49 years, no recommendations for prioritization of
LAIV use are made. ACIP has not indicated a preference for
LAIV or TIV when considering vaccination of healthy, non-
pregnant persons aged 5–49 years. However, during short-
ages of TIV, LAIV should be used preferentially when feasible
for all healthy persons aged 5–49 years (including HCP) who
desire or are recommended for vaccination to increase the avail-
ability of inactivated vaccine for persons at high risk.
Timing of Vaccination
Vaccination efforts should be structured to ensure the vac-
cination of as many persons as possible over the course of
several months, with emphasis on vaccinating as many per-
sons as possible before influenza activity in the community
begins. Even if vaccine distribution begins before October,
distribution probably will not be completed until December
or January. The following recommendations reflect this phased
distribution of vaccine.
In any given year, the optimal time to vaccinate patients
cannot be determined because influenza seasons vary in their
timing and duration, and more than one outbreak might
occur in a single community in a single year. In the United
States, localized outbreaks that indicate the start of seasonal
influenza activity can occur as early as October. However, in
>80% of influenza seasons since 1976, peak influenza activity
(which is often close to the midpoint of influenza activity for
the season) has not occurred until January or later, and in
>60% of seasons, the peak was in February or later (Table 1).
In general, health-care providers should begin offering vacci-
nation soon after vaccine becomes available and if possible by
October. To avoid missed opportunities for vaccination, pro-
viders should offer vaccination during routine health-care visits
or during hospitalizations whenever vaccine is available.
Vaccination efforts should continue throughout the season,
because the duration of the influenza season varies, and influ-
enza might not appear in certain communities until February
or March. Providers should offer influenza vaccine routinely,
and organized vaccination campaigns should continue
throughout the influenza season, including after influenza
activity has begun in the community. Vaccine administered in
December or later, even if influenza activity has already begun,
is likely to be beneficial in the majority of influenza seasons.
The majority of adults have antibody protection against
influenza virus infection within 2 weeks after vaccination
(337,338).
Children aged 6 months–8 years who have not been vacci-
nated previously or who were vaccinated for the first time
during the previous season and received only 1 dose should
receive 2 doses of vaccine. These children should receive their
first dose as soon after vaccine becomes available as is feasible,
so both doses can be administered before the onset of influ-
enza activity.
Persons and institutions planning substantial organized
vaccination campaigns (e.g., health departments, occupational
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health clinics, and community vaccinators) should consider
scheduling these events after at least mid-October because the
availability of vaccine in any location cannot be ensured
consistently in early fall. Scheduling campaigns after mid-
October will minimize the need for cancellations because vac-
cine is unavailable. These vaccination clinics should be
scheduled through December, and later if feasible, with
attention to settings that serve children aged 6–59 months,
pregnant women, other persons aged <50 years at increased
risk for influenza-related complications, persons aged >50
years, HCP, and persons who are household contacts of chil-
dren aged <59 months or other persons at high risk. Planners
are encouraged to develop the capacity and flexibility to sched-
ule at least one vaccination clinic in December. Guidelines
for planning large-scale immunization clinics are available at
http://www.cdc.gov/flu/professionals/vaccination/
vax_clinic.htm.
During a vaccine shortage or delay, substantial proportions
of TIV doses may not be released and distributed until
November and December, or later. When the vaccine is sub-
stantially delayed or disease activity has not subsided, agen-
cies should consider offering vaccination clinics into January
and beyond as long as vaccine supplies are available. Cam-




Successful vaccination programs combine publicity and
education for HCP and other potential vaccine recipients, a
plan for identifying persons recommended for vaccination,
use of reminder/recall systems, assessment of practice-level
vaccination rates with feedback to staff, and efforts to remove
administrative and financial barriers that prevent persons from
receiving the vaccine, including use of standing orders pro-
grams (335,339). Since October 2005, the Centers for Medi-
care and Medicaid Services (CMS) has required nursing homes
participating in the Medicare and Medicaid programs to offer
all residents influenza and pneumococcal vaccines and to docu-
ment the results. According to the requirements, each resi-
dent is to be vaccinated unless contraindicated medically, the
resident or a legal representative refuses vaccination, or the
vaccine is not available because of shortage. This information
is to be reported as part of the CMS Minimum Data Set,
which tracks nursing home health parameters (340,341).
The use of standing orders programs by long-term–care
facilities (e.g., nursing homes and skilled nursing facilities),
hospitals, and home health agencies ensures that vaccination
is offered. Standing orders programs for both influenza vacci-
nation should be conducted under the supervision of a
licensed practitioner according to a physician-approved facil-
ity or agency policy by HCP trained to screen patients for
contraindications to vaccination, administer vaccine, and
monitor for adverse events. CMS has removed the physician
signature requirement for the administration of influenza and
pneumococcal vaccines to Medicare and Medicaid patients in
hospitals, long-term–care facilities, and home health agencies
(341). To the extent allowed by local and state law, these
facilities and agencies may implement standing orders for
influenza and pneumococcal vaccination of Medicare- and
Medicaid-eligible patients. Payment for influenza vaccine
under Medicare Part B is available (342,343). Other settings
(e.g., outpatient facilities, managed care organizations, assisted
living facilities, correctional facilities, pharmacies, and adult
workplaces) are encouraged to introduce standing orders pro-
grams as well (336). In addition, physician reminders (e.g., flag-
ging charts) and patient reminders are recognized strategies for
increasing rates of influenza vaccination. Persons for whom
influenza vaccine is recommended can be identified and vacci-
nated in the settings described in the following sections.
Outpatient Facilities Providing Ongoing Care
Staff in facilities providing ongoing medical care (e.g., phy-
sicians’ offices, public health clinics, employee health clinics,
hemodialysis centers, hospital specialty-care clinics, and out-
patient rehabilitation programs) should identify and label the
medical records of patients who should receive vaccination.
Vaccine should be offered during visits throughout the influ-
enza season. The offer of vaccination and its receipt or refusal
should be documented in the medical record. Patients for
whom vaccination is recommended and who do not have regu-
larly scheduled visits during the fall should be reminded by
mail, telephone, or other means of the need for vaccination.
Outpatient Facilities Providing Episodic
or Acute Care
Acute health-care facilities (e.g., emergency departments and
walk-in clinics) should offer vaccinations throughout the
influenza season to persons for whom vaccination is recom-
mended or provide written information regarding why, where,
and how to obtain the vaccine. This written information
should be available in languages appropriate for the popula-
tions served by the facility.
Nursing Homes and Other Residential
Long-Term–Care Facilities
Vaccination should be provided routinely to all residents of
chronic-care facilities. If possible, all residents should be vac-
cinated at one time, before influenza season. In the majority
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of seasons, TIV will become available to long-term–care
facilities in October or November, and vaccination should
commence as soon as vaccine is available. As soon as possible
after admission to the facility, the benefits and risks of vacci-
nation should be discussed and education materials provided.
Signed consent is not required (344). Residents admitted
after completion of the vaccination program at the facility
should be vaccinated at the time of admission through March.
Acute-Care Hospitals
Hospitals should serve as a key setting for identifying per-
sons at increased risk for influenza complications. Unvacci-
nated persons of all ages (including children) with high-risk
conditions and persons aged 6 months–4 years or >50 years
who are hospitalized at any time, beginning from the time
vaccine becomes available for the upcoming season and con-
tinuing through the season, should be offered and strongly
encouraged to receive influenza vaccine before they are dis-
charged. Standing orders to offer influenza vaccination to all
hospitalized persons should be considered.
Visiting Nurses and Others Providing Home
Care to Persons at High Risk
Nursing-care plans should identify patients for whom vac-
cination is recommended, and vaccine should be administered
in the home, if necessary as soon as influenza vaccine is avail-
able and throughout the influenza season. Caregivers and other
persons in the household (including children) should be
referred for vaccination.
Other Facilities Providing Services to Persons
Aged >50 Years
Facilities providing services to persons aged >50 years (e.g.,
assisted living housing, retirement communities, and recre-
ation centers) should offer unvaccinated residents, attendees,
and staff annual on-site vaccination before the start of the
influenza season. Continuing to offer vaccination through-
out the fall and winter months is appropriate. Efforts to vac-
cinate newly admitted patients or new employees also should
be continued, both to prevent illness and to avoid having these
persons serve as a source of new influenza infections. Staff
education should emphasize the need for influenza vaccine.
Health-Care Personnel
Health-care facilities should offer influenza vaccinations to
all HCP, including night, weekend, and temporary staff. Par-
ticular emphasis should be placed on providing vaccinations
to workers who provide direct care for persons at high risk for
influenza complications. Efforts should be made to educate
HCP regarding the benefits of vaccination and the potential
health consequences of influenza illness for their patients,
themselves, and their family members. All HCP should be
provided convenient access to influenza vaccine at the work
site, free of charge, as part of employee health programs
(309,320,321).
Future Directions for Research
and Recommendations Related
to Influenza Vaccine
The relatively low effectiveness of influenza vaccine admin-
istered to older adults highlights the need for more immuno-
genic influenza vaccines for the elderly (345) and for additional
research to understand potential biases in estimating the ben-
efits of vaccination among older adults in reducing hospital-
izations and deaths (90,346,347). Additional studies of the
relative cost-effectiveness and cost utility of influenza vacci-
nation among children and adults, especially those aged <65
years, are needed and should be designed to account for year-
to-year variations in influenza attack rates, illness severity,
hospitalization costs and rates, and vaccine effectiveness when
evaluating the long-term costs and benefits of annual vacci-
nation (348). Additional data also are needed to quantify the
benefits of influenza vaccination of HCP in protecting their
patients (259) and on the benefits of vaccinating children to
reduce influenza complications among those at risk. Because
of expansions in ACIP recommendations for vaccination and
the potential for a pandemic, much larger networks are needed
that can identify and assess the causality of very rare events
that occur after vaccination, including GBS. Research on
potential biologic or genomic risk factors for GBS also is
needed. However, research to develop more immunogenic
vaccines and document vaccine safety must be accompanied
by a better understanding of how to motivate persons at risk
to seek annual influenza vaccination.
ACIP continues to review new vaccination strategies to pro-
tect against influenza, including the possibility of expanding
routine influenza vaccination recommendations toward uni-
versal vaccination or other approaches that will help reduce
or prevent the transmission of influenza and reduce the bur-
den of severe disease (349–354). For example, expanding
annual vaccination recommendations to include older
children requires additional information on the potential
communitywide protective effects and cost, additional plan-
ning to improve surveillance systems capable of monitoring
effectiveness and safety, and further development of imple-
mentation strategies. In addition, as noted by the National
Vaccine Advisory Committee, strengthening the U.S. influ-
enza vaccination system will require improving vaccine financ-
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ing and demand and implementing systems to help better
understand the burden of influenza in the United States (355).
Immunization programs capable of delivering annual influ-
enza vaccination to a broad range of the population could
potentially serve as a resilient and sustainable platform for
delivering vaccines and monitoring outcomes for other
urgently required public health interventions (e.g., vaccines
for pandemic influenza or medications to prevent or treat ill-
nesses caused by acts of terrorism).
Seasonal Influenza Vaccine
and Avian Influenza
Sporadic human cases of infection with highly pathogenic
avian influenza A (H5N1) viruses have been identified in Asia,
Africa, and the Middle East, primarily among persons who
have had close contact with sick or dead birds (356–361). To
date, no evidence exists of genetic reassortment between
human influenza A and H5N1 viruses. However, influenza
viruses derived from strains currently circulating in animals
(e.g., the H5N1 viruses that have caused outbreaks of avian
influenza and occasionally have infected humans) have the
potential to recombine with human influenza A viruses
(362,363).
To date, highly pathogenic H5N1 influenza viruses have
not been identified in wild or domestic birds or in humans in
the United States. Current seasonal influenza vaccines pro-
vide no protection against human infection with avian influ-
enza A viruses, including H5N1. However, reducing seasonal
influenza risk through influenza vaccination of persons who
might be exposed to nonhuman influenza viruses (e.g., H5N1
viruses) might reduce the theoretical risk for recombination
of an avian influenza A virus and a human influenza A virus
by preventing seasonal influenza virus infection within a
human host. CDC has recommended that persons who are
charged with responding to avian influenza outbreaks among
poultry receive seasonal influenza vaccination (364). As part
of preparedness activities, the Occupational Safety and Health
Administration (OSHA) has issued an advisory notice regard-
ing poultry worker safety that is intended for implementation
in the event of a suspected or confirmed avian flu outbreak at
a poultry facility in the United States. OSHA guidelines rec-
ommend that poultry workers in an involved facility receive
vaccination against seasonal influenza; OSHA also has rec-
ommended that HCP involved in the care of patients with
documented or suspected AI should be vaccinated with the
most recent seasonal human influenza vaccine to reduce the
risk for co-infection with human influenza A viruses (365).
Human infection with novel influenza A virus strains, includ-
ing influenza A viruses that cause avian influenza, is now a
nationally notifiable disease (366).
Recommendations for Using
Antiviral Agents for Seasonal
Influenza
Although annual vaccination is the primary strategy for pre-
venting complications of influenza virus infections, antiviral
medications with activity against influenza viruses can be
effective for the chemoprophylaxis and treatment of influenza.
Four licensed influenza antiviral agents are available in the
United States: amantadine, rimantadine, zanamivir, and
oseltamivir. Influenza A virus resistance to amantadine and
rimantadine can emerge rapidly during treatment. Because
antiviral testing results indicated high levels of resistance (367–
370), neither amantadine nor rimantadine should be used for
the treatment or chemoprophylaxis of influenza in the United
States during the 2007–08 influenza season. Surveillance dem-
onstrating that susceptibility to these antiviral medications has
been reestablished among circulating influenza A viruses will
be needed before amantadine or rimantadine can be used for
the treatment or chemoprophylaxis of influenza A. Oseltamivir
or zanamivir can be prescribed if antiviral treatment of influ-
enza is indicated. Oseltamivir is approved for treatment of
persons aged >1 year, and zanamivir is approved for treating
persons aged >7 years. Oseltamivir and zanamivir can be used
for chemoprophylaxis of influenza; oseltamivir is licensed for
use as chemoprophylaxis in persons aged >1 year, and
zanamivir is licensed for use in persons aged >5 years.
Antiviral Agents for Influenza
Zanamivir and oseltamivir are chemically related antiviral
medications known as neuraminidase inhibitors that have
activity against both influenza A and B viruses. The two medi-
cations differ in pharmacokinetics, adverse events, routes of
administration, approved age groups, dosages, and costs. An
overview of the indications, use, administration, and known
primary adverse events of these medications is presented in
the following sections. Package inserts should be consulted
for additional information. Detailed information about aman-
tadine and rimantadine is available in previous ACIP influ-
enza recommendations (371).
Role of Laboratory Diagnosis
Appropriate treatment of patients with respiratory illness
depends on both accurate and timely diagnosis. Influenza sur-
veillance information and diagnostic testing can aid clinical
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judgment and help guide treatment decisions. For example,
early diagnosis of influenza can reduce the inappropriate use
of antibiotics and provide the option of using antiviral therapy.
However, because certain bacterial infections can produce
symptoms similar to influenza, if bacterial infections are sus-
pected, they should be considered and treated appropriately.
In addition, secondary invasive bacterial infections can be a
severe complication of influenza.
The accuracy of clinical diagnosis of influenza on the basis
of symptoms alone is limited because symptoms from illness
caused by other pathogens can overlap considerably with
influenza (26,39,40). Influenza surveillance by state and local
health departments and CDC can provide information
regarding the circulation of influenza viruses in the commu-
nity. Surveillance also can identify the predominant circulat-
ing types, influenza A subtypes, and strains of influenza viruses.
Diagnostic tests available for influenza include viral culture,
serology, rapid antigen testing, reverse transcriptase-polymerase
chain reaction (RT-PCR), and immunofluorescence assays
(372). Sensitivity and specificity of any test for influenza can
vary by the laboratory that performs the test, the type of test
used, the type of specimen tested, the quality of the specimen,
and the timing of specimen collection in relation to illness
onset. Among respiratory specimens for viral isolation or rapid
detection of influenza viruses, nasopharyngeal and nasal speci-
mens have higher yields than throat swab specimens (373).
As with any diagnostic test, results should be evaluated in the
context of other clinical and epidemiologic information avail-
able to health-care providers. In addition, positive influenza tests
have been reported up to 7 days after receipt of LAIV (374).
Commercial rapid diagnostic tests are available that can
detect influenza viruses within 30 minutes (375,376). Cer-
tain tests are approved for use in any outpatient setting, whereas
others must be used in a moderately complex clinical labora-
tory. These rapid tests differ in the types of influenza viruses
they can detect and whether they can distinguish between
influenza types. Different tests can detect 1) only influenza
A viruses; 2) both influenza A and B viruses, but not distin-
guish between the two types; or 3) both influenza A and B
and distinguish between the two. None of the rapid influ-
enza diagnostic tests provides any information on influenza A
subtypes.
The types of specimens acceptable for use (i.e., throat,
nasopharyngeal, or nasal aspirates, swabs, or washes) also vary
by test, but all perform best when collected as close to illness
onset as possible. The specificity and, in particular, the sensi-
tivity of rapid tests are lower than for viral culture and vary by
test (372,375–377). Because of the lower sensitivity of the
rapid tests, physicians should consider confirming negative
tests with viral culture or other means because of the possibil-
ity of false-negative rapid test results, especially during peri-
ods of peak community influenza activity. Because the positive
predictive value of rapid tests will be lower during periods of
low influenza activity, when interpreting results of a rapid
influenza test, physicians should consider the positive and nega-
tive predictive values of the test in the context of the level of
influenza activity in their community (377). Package inserts
and the laboratory performing the test should be consulted
for more details regarding use of rapid diagnostic tests.
Additional updated information concerning diagnostic test-
ing is available at http://www.cdc.gov/flu/professionals/lab
diagnosis.htm.
Despite the availability of rapid diagnostic tests, collecting
clinical specimens for viral culture is critical for surveillance
purposes and can be helpful in clinical management. Only
culture isolates of influenza viruses can provide specific infor-
mation regarding circulating strains and subtypes of influenza
viruses and data on antiviral resistance. This information is
needed to compare current circulating influenza strains with
vaccine strains, to guide decisions regarding influenza treat-
ment and chemoprophylaxis, and to formulate vaccine for
the coming year. Virus isolates also are needed to monitor
antiviral resistance and the emergence of novel influenza A
subtypes that might pose a pandemic threat.
Antiviral Drug-Resistant Strains
of Influenza
Adamantane resistance among circulating influenza A
viruses has increased rapidly worldwide over the past several
years. The proportion of influenza A viral isolates submitted
from throughout the world to the World Health Organiza-
tion Collaborating Center for Surveillance, Epidemiology, and
Control of Influenza at CDC that were adamantane-resistant
increased from 0.4% during 1994–1995 to 12.3% during
2003–2004 (378). During the 2005–06 influenza season,
CDC determined that 193 (92%) of 209 influenza A (H3N2)
viruses isolated from patients in 26 states demonstrated a
change at amino acid 31 in the M2 gene that confers resis-
tance to adamantanes (367,368). In addition, two (25%) of
eight influenza A (H1N1) viruses tested were resistant (368).
All 2005–06 influenza season isolates in these studies remained
sensitive to neuraminidase inhibitors (367–369). Preliminary
data from the 2006–07 influenza season indicates that resis-
tance to adamantanes remains high among influenza A iso-
lates, but resistance to neuraminidase inhibitors is extremely
uncommon (<1% of isolates) (CDC, unpublished data, 2007).
Amantadine or rimantidine should not be used for the treat-
ment or prevention of influenza in the United States until
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evidence of susceptibility to these antiviral medications has
been reestablished among circulating influenza A viruses.
Influenza A viral resistance to adamantanes can emerge rap-
idly during treatment because a single point mutation at amino
acid positions 26, 27, 30, 31, or 34 of the M2 protein can
confer cross resistance to both amantadine and rimantadine
(379,380). Adamantane-resistant influenza A virus strains can
emerge in approximately one third of patients when either
amantadine or rimantadine is used for therapy (379,381,382).
Resistant influenza A virus strains can replace susceptible
strains within 2–3 days of starting amantadine or rimantadine
therapy (383,384). Resistant influenza A viruses have been
isolated from persons who live at home or in an institution in
which other residents are taking or have recently taken aman-
tadine or rimantadine as therapy (385,386). Persons who have
influenza A virus infection and who are treated with either
amantadine or rimantadine can shed susceptible viruses early
in the course of treatment and later shed drug-resistant viruses,
including after 5–7 days of therapy (381).
Resistance to zanamivir and oseltamivir can be induced in
influenza A and B viruses in vitro (387–394), but induction
of resistance typically requires multiple passages in cell cul-
ture. By contrast, resistance to amantadine and rimantadine
in vitro can be induced with fewer passages in cell culture
(395,396). Development of viral resistance to zanamivir or
oseltamivir during treatment has been identified but does not
appear to be frequent (397–401). One limited study reported
that oseltamivir-resistant influenza A viruses were isolated from
nine (18%) of 50 Japanese children during treatment with
oseltamivir (402). Transmission of neuraminidase inhibitor-
resistant influenza B viruses between humans is rare but has
been documented (403). No isolates with reduced suscepti-
bility to zanamivir have been reported from clinical trials,
although the number of posttreatment isolates tested is lim-
ited (404,405). Only one clinical isolate with reduced suscep-
tibility to zanamivir, obtained from an immunocompromised
child on prolonged therapy, has been reported (405).
Laboratory studies suggest that influenza viruses with
oseltamivir resistance have diminished replication competence
and infectivity. However, prolonged shedding of oseltamivir-
or zanamivir-resistant virus by severely immunocompromised
patients, even after cessation of oseltamivir treatment, has been
reported (406–407). Tests that can detect clinical resistance
to the neuraminidase inhibitor antiviral drugs are being
developed (404,408), and postmarketing surveillance for
neuraminidase inhibitor–resistant influenza viruses is being
conducted. Among 2,287 isolates obtained from multiple
countries during 1999–2002, only eight (0.33%) had a greater-
than-tenfold decrease in susceptibility to oseltamivir, and two
(25%) of these eight also were resistant to zanamivir (409).
Indications for Use of Antivirals When
Susceptibility Exists
Treatment
Initiation of antiviral treatment within 2 days of illness
onset is recommended, although the benefit of treatment is
greater as the time after illness onset is reduced. The benefit of
antiviral treatment when initiated >2 days after illness onset is
minimal for uncomplicated influenza. However, no data are
available on the benefit for severe influenza when antiviral
treatment is initiated >2 days after illness onset. The recom-
mended duration of treatment with either zanamivir or
oseltamivir is 5 days.
Evidence for the effectiveness of these antiviral drugs is based
primarily on studies of outpatients with uncomplicated influ-
enza. Few data are available about the effectiveness of antivi-
ral drug treatment for hospitalized patients with complications
of influenza. When administered within 2 days of illness
onset to otherwise healthy children or adults, zanamivir or
oseltamivir can reduce the duration of uncomplicated influ-
enza A and B illness by approximately 1 day compared with
placebo (133,410–425). Minimal or no benefit is reported
when antiviral treatment is initiated >2 days after onset of
uncomplicated influenza. Data on whether viral shedding is
reduced are inconsistent. The duration of viral shedding was
reduced in one study that employed experimental infection;
however, other studies have not demonstrated reduction in
the duration of viral shedding. A recent review that examined
neuraminidase inhibitor effect on reducing ILI concluded that
neuraminidase inhibitors were not effective in the control of
seasonal influenza (426). However, lower or no efficacy using
a nonspecific (compared with laboratory-confirmed influenza)
clinical endpoint such as ILI would be expected (427).
More clinical data are available concerning the efficacy of
zanamivir and oseltamivir for treatment of influenza A virus
infection than for treatment of influenza B virus infection
(414,428–438). Data from in vitro studies, treatment studies
among mice and ferrets (439–445), and human clinical stud-
ies have indicated that zanamivir and oseltamivir have activ-
ity against influenza B viruses (397,404,414,419,446,447).
However, an observational study among Japanese children with
culture-confirmed influenza and treated with oseltamivir dem-
onstrated that children with influenza A virus infection
resolved fever and stopped shedding virus more quickly than
children with influenza B, suggesting that oseltamivir is less
effective for the treatment of influenza B (448).
Data are limited regarding the effectiveness of zanamivir
and oseltamivir in preventing serious influenza-related com-
plications (e.g., bacterial or viral pneumonia or exacerbation
of chronic diseases), or for preventing influenza among per-
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sons at high risk for serious complications of influenza
(411,412,414,415,419–431). In a study that combined data
from 10 clinical trials, the risk for pneumonia among those
participants with laboratory-confirmed influenza receiving
oseltamivir was approximately 50% lower than among those
persons receiving a placebo and 34% lower among patients at
risk for complications (p<0.05 for both comparisons) (432).
Although a similar significant reduction also was determined
for hospital admissions among the overall group, the 50%
reduction in hospitalizations reported in the small subset of
high-risk participants was not statistically significant. One
randomized controlled trial documented a decreased incidence
of otitis media among children treated with oseltamivir (413).
Another randomized controlled study conducted among
influenza-infected children with asthma demonstrated signifi-
cantly greater improvement in lung function and fewer asthma
exacerbations among oseltamivir-treated children compared
with those who received placebo but did not determine a dif-
ference in symptom duration (449). Inadequate data exist
regarding the efficacy of any of the influenza antiviral drugs
for use among children aged <1 year, and none are FDA-
approved for use in this age group (371).
Chemoprophylaxis
Chemoprophylactic drugs are not a substitute for vaccina-
tion, although they are critical adjuncts in preventing and
controlling influenza. In community studies of healthy adults,
both oseltamivir and zanamivir had similar efficacy in pre-
venting febrile, laboratory-confirmed influenza illness (effi-
cacy: zanamivir, 84%; oseltamivir, 82%) (414,433). Both
antiviral agents also have prevented influenza illness among
persons administered chemoprophylaxis after a household
member had influenza diagnosed (efficacy: zanamivir, 72%–
82%; oseltamivir, 68%–89%) (434,446,450,451). Experience
with prophylactic use of these agents in institutional settings
or among patients with chronic medical conditions is limited
in comparison with the adamantanes, but the majority of
published studies have demonstrated moderate to excellent
efficacy (397,430,431,435–437). For example, a 6-week study
of oseltamivir chemoprophylaxis among nursing home resi-
dents demonstrated a 92% reduction in influenza illness (452).
The efficacy of antiviral agents in preventing influenza among
severely immunocompromised persons is unknown. A small
nonrandomized study conducted in a stem cell transplant unit
suggested that oseltamivir can prevent progression to pneu-
monia among influenza-infected patients (453).
When determining the timing and duration for adminis-
tering influenza antiviral medications for chemoprophylaxis,
factors related to cost, compliance, and potential adverse events
should be considered. To be maximally effective as chemo-
prophylaxis, the drug must be taken each day for the duration
of influenza activity in the community. Currently, oseltamivir
is the recommended antiviral drug for chemoprophylaxis of
influenza.
Persons at High Risk Who Are Vaccinated
After Influenza Activity Has Begun
Development of antibodies in adults after vaccination takes
approximately 2 weeks (337,338). Therefore, when influenza
vaccine is administered after influenza activity in a commu-
nity has begun, chemoprophylaxis should be considered for
persons at high risk during the time from vaccination until
immunity has developed. Children aged <9 years who receive
TIV for the first time might require as much as 6 weeks of
chemoprophylaxis (i.e., chemoprophylaxis for 4 weeks after
the first dose of TIV and an additional 2 weeks of chemopro-
phylaxis after the second dose). Persons at high risk for com-
plications of influenza still can benefit from vaccination after
community influenza activity has begun because influenza
viruses might still be circulating at the time vaccine-induced
immunity is achieved.
Persons Who Provide Care to Those
at High Risk
To reduce the spread of virus to persons at high risk, chemo-
prophylaxis during peak influenza activity can be considered
for unvaccinated persons who have frequent contact with per-
sons at high risk. Persons with frequent contact might include
employees of hospitals, clinics, and chronic-care facilities,
household members, visiting nurses, and volunteer workers.
If an outbreak is caused by a strain of influenza that might
not be covered by the vaccine, chemoprophylaxis can be con-
sidered for all such persons, regardless of their vaccination
status.
Persons Who Have Immune Deficiencies
Chemoprophylaxis can be considered for persons at high
risk who are more likely to have an inadequate antibody
response to influenza vaccine. This category includes persons
infected with HIV, chiefly those with advanced HIV disease.
No published data are available concerning possible efficacy
of chemoprophylaxis among persons with HIV infection or
interactions with other drugs used to manage HIV infection.
Such patients should be monitored closely if chemoprophy-
laxis is administered.
Other Persons
Chemoprophylaxis throughout the influenza season or dur-
ing increases in influenza activity within the community might
be appropriate for persons at high risk for whom vaccination
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is contraindicated. Chemoprophylaxis also can be offered to
persons who wish to avoid influenza illness. Health-care pro-
viders and patients should make decisions regarding whether
to begin chemoprophylaxis and how long to continue it on
an individual basis.
Control of Influenza Outbreaks in Institutions
Use of antiviral drugs for treatment and chemoprophylaxis
of influenza is a key component of influenza outbreak control
in institutions. In addition to antiviral medications, other
outbreak-control measures include instituting droplet precau-
tions and establishing cohorts of patients with confirmed or
suspected influenza, re-offering influenza vaccinations to
unvaccinated staff and patients, restricting staff movement
between wards or buildings, and restricting contact between
ill staff or visitors and patients (454–456).
The majority of published reports concerning use of antivi-
ral agents to control influenza outbreaks in institutions are
based on studies of influenza A outbreaks among persons in
nursing homes who received amantadine or rimantadine (457–
461). Less information is available concerning use of
neuraminidase inhibitors in influenza A or B institutional
outbreaks (430,431,436,452,462). When confirmed or sus-
pected outbreaks of influenza occur in institutions that house
persons at high risk, chemoprophylaxis should be started as
early as possible to reduce the spread of the virus. In these
situations, having preapproved orders from physicians or plans
to obtain orders for antiviral medications on short notice can
substantially expedite administration of antiviral medications.
When outbreaks occur in institutions, chemoprophylaxis
should be administered to all eligible residents, regardless of
whether they received influenza vaccinations during the pre-
vious fall, and should continue for a minimum of 2 weeks. If
surveillance indicates that new cases continue to occur, chemo-
prophylaxis should be continued until approximately 1 week
after the end of the outbreak. Chemoprophylaxis also can be
offered to unvaccinated staff members who provide care to
persons at high risk. Chemoprophylaxis should be considered
for all employees, regardless of their vaccination status, if
indications exist that the outbreak is caused by a strain of
influenza virus that is not well-matched by the vaccine. Such
indications might include multiple documented breakthrough
influenza-virus infections among vaccinated persons or circu-
lation in the surrounding community of suspected index case(s)
of strains not contained in the vaccine.
In addition to use in nursing homes, chemoprophylaxis also
can be considered for controlling influenza outbreaks in other
closed or semiclosed settings (e.g., dormitories, correctional
facilities, or other settings in which persons live in close prox-
imity). To limit the potential transmission of drug-resistant
virus during outbreaks in institutions, whether in chronic or
acute-care settings or other closed settings, measures should
be taken to reduce contact between persons taking antiviral
drugs for treatment and other persons, including those taking
chemoprophylaxis.
Dosage
Dosage recommendations vary by age group and medical
conditions (Table 6).
Adults
Zanamivir. Zanamivir is approved for treatment of adults
with uncomplicated acute illness caused by influenza A or B
virus, and for chemoprophylaxis of influenza among adults.
Zanamivir is not recommended for persons with underlying
airways disease (e.g., asthma or chronic obstructive pulmo-
nary diseases).
Oseltamivir. Oseltamivir is approved for treatment of adults
with uncomplicated acute illness caused by influenza A or B
virus and for chemoprophylaxis of influenza among adults.
Dosages and schedules for adults are listed (Table 6).
Children
Zanamivir. Zanamivir is approved for treatment of influ-
enza among children aged >7 years. The recommended dos-
age of zanamivir for treatment of influenza is 2 inhalations
(one 5-mg blister per inhalation for a total dose of 10 mg)
twice daily (approximately 12 hours apart). Zanamivir is
approved for chemoprophylaxis of influenza among children
aged >5 years; the chemoprophylaxis dosage of zanamivir for
children aged >5 years is 10 mg (2 inhalations) once a day
(405,463).
Oseltamivir. Oseltamivir is approved for treatment and
chemoprophylaxis among children aged >1 year. Recom-
mended treatment dosages vary by the weight of the child: 30
mg twice a day for children who weigh <15 kg, 45 mg twice a
day for children who weigh >15–23 kg, 60 mg twice a day for
those who weigh >23–40 kg, and 75 mg twice a day for those
who weigh >40 kg (397,463). Dosages for chemoprophylaxis
are the same for each weight group, but doses are adminis-
tered only once per day rather than twice.
Persons Aged >65 Years
Zanamivir and Oseltamivir. No reduction in dosage is rec-
ommended on the basis of age alone.
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Persons with Impaired Renal Function
Zanamivir. Limited data are available regarding the safety
and efficacy of zanamivir for patients with impaired renal func-
tion. Among patients with renal failure who were adminis-
tered a single intravenous dose of zanamivir, decreases in renal
clearance, increases in half-life, and increased systemic expo-
sure to zanamivir were reported (405). However, a limited
number of healthy volunteers who were administered high
doses of intravenous zanamivir tolerated systemic levels of
zanamivir that were substantially higher than those resulting
from administration of zanamivir by oral inhalation at the
recommended dose (464,465). On the basis of these consid-
erations, the manufacturer recommends no dose adjustment
for inhaled zanamivir for a 5-day course of treatment for
patients with either mild-to-moderate or severe impairment
in renal function (405).
Oseltamivir. Serum concentrations of oseltamivir carboxy-
late, the active metabolite of oseltamivir, increase with declin-
ing renal function (397,466). For patients with creatinine
clearance of 10–30 mL per minute (397), a reduction of the
treatment dosage of oseltamivir to 75 mg once daily and in
the chemoprophylaxis dosage to 75 mg every other day is rec-
ommended. No treatment or chemoprophylaxis dosing rec-
ommendations are available for patients undergoing routine
renal dialysis treatment.
Persons with Liver Disease
Use of zanamivir or oseltamivir has not been studied among
persons with hepatic dysfunction.
Persons with Seizure Disorders
Seizure events have been reported during postmarketing use
of zanamivir and oseltamivir, although no epidemiologic stud-
ies have reported any increased risk for seizures with either
zanamivir or oseltamivir use.
Route
Oseltamivir is administered orally in capsule or oral sus-
pension form. Zanamivir is available as a dry powder that is
self-administered via oral inhalation by using a plastic device
included in the package with the medication. Patients should
be instructed about the correct use of this device.
Pharmacokinetics
Zanamivir
In studies of healthy volunteers, approximately 7%–21%
of the orally inhaled zanamivir dose reached the lungs, and
70%–87% was deposited in the oropharynx (405,467).
Approximately 4%–17% of the total amount of orally inhaled
zanamivir is absorbed systemically. Systemically absorbed
TABLE 6. Recommended daily dosage of influenza antiviral medications for treatment and chemoprophylaxis — United States
Age group (yrs)
Antiviral agent 1–6 7–9 10–12 13–64 >65
Zanamivir*
Treatment, NA† 10 mg (2 inhalations) 10 mg (2 inhalations) 10 mg (2 inhalations) 10 mg (2 inhalations)
influenza A and B twice daily twice daily twice daily twice daily
1–4 5–9
Chemoprophylaxis, NA 10 mg (2 inhalations) 10 mg (2 inhalations) 10 mg (2 inhalations) 10 mg (2 inhalations)
influenza A and B once daily once daily once daily once daily
Oseltamivir
Treatment,§ Dose varies by Dose varies by Dose varies by 75 mg twice daily 75 mg twice daily
influenza A and B child’s weight¶ child’s weight¶ child’s weight¶
Chemoprophylaxis, Dose varies by Dose varies by Dose varies by 75 mg/day 75 mg/day
influenza A and B child’s weight** child’s weight** child’s weight**
NOTE: Zanamivir is manufactured by GlaxoSmithKline (Relenza® — inhaled powder). Zanamivir is approved for treatment of persons aged >7 years and
approved for chemoprophylaxis of persons aged >5 years. Oseltamivir is manufactured by Roche Pharmaceuticals (Tamiflu® — tablet). Oseltamivir is
approved for treatment or chemoprophylaxis of persons aged >1 year. No antiviral medications are approved for treatment or chemoprophylaxis of influenza
among children aged <1 year. This information is based on data published by the Food and Drug Administration (available at http://www.fda.gov).
* Zanamivir is administered through oral inhalation by using a plastic device included in the medication package. Patients will benefit from instruction and
demonstration of the correct use of the device. Zanamivir is not recommended for those persons with underlying airway disease.
† Not applicable.
§ A reduction in the dose of oseltamivir is recommended for persons with creatinine clearance <30 mL/min.
¶ The treatment dosing recommendation for children weighing <15 kg is 30 mg twice a day; for children weighing >15–23 kg, the dose is 45 mg twice a day;
for children weighing >23–40 kg, the dose is 60 mg twice a day; and for children weighing >40 kg, the dose is 75 mg twice a day.
** The chemoprophylaxis dosing recommendation for children weighing <15 kg is 30 mg once a day; for children weighing >15–23 kg, the dose is 45 mg once
a day; for children weighing >23–40 kg, the dose is 60 mg once a day; and for children weighing >40 kg, the dose is 75 mg once a day.
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zanamivir has a half-life of 2.5–5.1 hours and is excreted
unchanged in the urine. Unabsorbed drug is excreted in the
feces (405,465).
Oseltamivir
Approximately 80% of orally administered oseltamivir is
absorbed systemically (466). Absorbed oseltamivir is metabo-
lized to oseltamivir carboxylate, the active neuraminidase
inhibitor, primarily by hepatic esterases. Oseltamivir carboxy-
late has a half-life of 6–10 hours and is excreted in the urine
by glomerular filtration and tubular secretion via the anionic
pathway (397,468). Unmetabolized oseltamivir also is excreted
in the urine by glomerular filtration and tubular secretion
(468).
Adverse Events
When considering use of influenza antiviral medications
(i.e., choice of antiviral drug, dosage, and duration of therapy),
clinicians must consider the patient’s age, weight, and renal
function (Table 6); presence of other medical conditions;
indications for use (i.e., chemoprophylaxis or therapy); and
the potential for interaction with other medications.
Zanamivir
Limited data are available regarding the safety or efficacy of
zanamivir for persons with underlying respiratory disease or
for persons with complications of acute influenza, and
zanamivir is approved only for use in persons without under-
lying respiratory or cardiac disease (469). In a study of
zanamivir treatment of ILI among persons with asthma or
chronic obstructive pulmonary disease in which study medi-
cation was administered after use of a B2-agonist, 13% of
patients receiving zanamivir and 14% of patients who received
placebo (inhaled powdered lactose vehicle) experienced a >20%
decline in forced expiratory volume in 1 second (FEV1) after
treatment (405,430). However, in a phase-I study of persons
with mild or moderate asthma who did not have ILI, one of
13 patients experienced bronchospasm after administration
of zanamivir (405). In addition, during postmarketing sur-
veillance, cases of respiratory function deterioration after
inhalation of zanamivir have been reported. Because of the
risk for serious adverse events and because the efficacy has not
been demonstrated among this population, zanamivir is not
recommended for treatment for patients with underlying air-
way disease (405). Allergic reactions, including oropharyn-
geal or facial edema, also have been reported during
postmarketing surveillance (405,430).
In clinical treatment studies of persons with uncomplicated
influenza, the frequencies of adverse events were similar for
persons receiving inhaled zanamivir and for those receiving
placebo (i.e., inhaled lactose vehicle alone) (410–415,430).
The most common adverse events reported by both groups
were diarrhea, nausea, sinusitis, nasal signs and symptoms,
bronchitis, cough, headache, dizziness, and ear, nose, and
throat infections. Each of these symptoms was reported by
<5% of persons in the clinical treatment studies combined
(405). Zanamivir does not impair the immunologic response
to TIV (470).
Oseltamivir
Nausea and vomiting were reported more frequently among
adults receiving oseltamivir for treatment (nausea without
vomiting, approximately 10%; vomiting, approximately 9%)
than among persons receiving placebo (nausea without vom-
iting, approximately 6%; vomiting, approximately 3%)
(397,416,417,471). Among children treated with oseltamivir,
14% had vomiting, compared with 8.5% of placebo recipi-
ents. Overall, 1% discontinued the drug secondary to this
side effect (419), whereas a limited number of adults who
were enrolled in clinical treatment trials of oseltamivir dis-
continued treatment because of these symptoms (397). Simi-
lar types and rates of adverse events were reported in studies
of oseltamivir chemoprophylaxis (397). Nausea and vomiting
might be less severe if oseltamivir is taken with food (397).
No published studies have assessed whether oseltamivir
impairs the immunologic response to TIV.
Transient neuropsychiatric events (self-injury or delirium)
have been reported postmarketing among persons taking
oseltamivir; the majority of reports were among adolescents
and adults living in Japan (472). FDA advises that persons
receiving oseltamivir be monitored closely for abnormal
behavior (397).
Use During Pregnancy
Oseltamivir and zanamivir are both “Pregnancy Category
C” medications, indicating that no clinical studies have been
conducted to assess the safety of these medications for preg-
nant women. Because of the unknown effects of influenza
antiviral drugs on pregnant women and their fetuses, these
two drugs should be used during pregnancy only if the poten-
tial benefit justifies the potential risk to the embryo or fetus;
the manufacturers’ package inserts should be consulted
(397,405). However, no adverse effects have been reported
among women who received oseltamivir or zanamivir during
pregnancy or among infants born to such women.
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Drug Interactions
Clinical data are limited regarding drug interactions with
zanamivir. However, no known drug interactions have been
reported, and no clinically critical drug interactions have been
predicted on the basis of in vitro and animal study data
(397,405,473).
Limited clinical data are available regarding drug interac-
tions with oseltamivir. Because oseltamivir and oseltamivir
carboxylate are excreted in the urine by glomerular filtration
and tubular secretion via the anionic pathway, a potential
exists for interaction with other agents excreted by this path-
way. For example, coadministration of oseltamivir and
probenecid resulted in reduced clearance of oseltamivir car-
boxylate by approximately 50% and a corresponding approxi-
mate twofold increase in the plasma levels of oseltamivir
carboxylate (468).
No published data are available concerning the safety or
efficacy of using combinations of any of these influenza anti-
viral drugs. Package inserts should be consulted for more
detailed information about potential drug interactions.
Sources of Information Regarding
Influenza and Its Surveillance
Information regarding influenza surveillance, prevention,
detection, and control is available at http://www.cdc.gov/
flu. During October–May, surveillance information is
updated weekly. In addition, periodic updates regarding
influenza are published in the MMWR Weekly Report
(http://www.cdc.gov/mmwr). Additional information regard-
ing influenza vaccine can be obtained by calling 1-800-CDC-
INFO (1-800-232-4636). State and local health departments
should be consulted concerning availability of influenza vac-
cine, access to vaccination programs, information related to
state or local influenza activity, reporting of influenza out-
breaks and influenza-related pediatric deaths, and advice
concerning outbreak control.
Responding to Adverse Events
After Vaccination
Health-care professionals should report all clinically signifi-
cant adverse events after influenza vaccination promptly to
VAERS, even if the health-care professional is not certain that
the vaccine caused the event. Clinically significant adverse
events that follow vaccination should be reported at http://
www.vaers.hhs.gov. Reports may be filed securely online or
by telephone at 1-800-822-7967 to request reporting forms
or other assistance.
The National Vaccine Injury Compensation Program
(VICP), established by the National Childhood Vaccine
Injury Act of 1986, as amended, provides a mechanism
through which compensation can be paid on behalf of a per-
son determined to have been injured or to have died as a
result of receiving a vaccine covered by VICP. The Vaccine
Injury Table lists the vaccines covered by VICP and the inju-
ries and conditions (including death) for which compensa-
tion might be paid. If the injury or condition is not on the
Table, or does not occur within the specified time period on
the Table, persons must prove that the vaccine caused the
injury or condition.
For a person to be eligible for compensation, the general
filing deadlines for injuries require claims to be filed within 3
years after the first symptom of the vaccine injury; for a death,
claims must be filed within 2 years of the vaccine-related death
and not more than 4 years after the start of the first symptom
of the vaccine-related injury from which the death occurred.
When a new vaccine is covered by VICP or when a new in-
jury/condition is added to the Table, claims that do not meet
the general filing deadlines must be filed within 2 years from
the date the vaccine or injury/condition is added to the Table
for injuries or deaths that occurred up to 8 years before the
Table change. Persons of all ages who receive a VICP-covered
vaccine might be eligible to file a claim. Both the intranasal
(LAIV) and injectable (TIV) trivalent influenza vaccines are
covered under VICP. Additional information about VICP is
available at http//www.hrsa.gov/vaccinecompensation or by
calling 1-800-338-2382.
Reporting of Serious Adverse Events
After Antiviral Medications
Severe adverse events associated with the administration of
antiviral medications used to prevent or treat influenza (e.g.,
those resulting in hospitalization or death) should be reported
to MedWatch, FDA’s Safety Information and Adverse Event
Reporting Program, at telephone 1-800-FDA-1088, by
facsimile at 1-800-FDA-0178, or via the Internet by sending
Report Form 3500 (available at http://www.fda.gov/med
watch/safety/3500.pdf ). Instructions regarding the types of
adverse events that should be reported are included on
MedWatch report forms.
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Additional Information Regarding
Influenza Virus Infection Control
Among Specific Populations
Each year, ACIP provides general, annually updated infor-
mation regarding control and prevention of influenza. Other
reports related to controlling and preventing influenza among
specific populations (e.g., immunocompromised persons,
HCP, hospital patients, pregnant women, children, and trav-
elers) also are available in the following publications:
• CDC. General recommendations on immunization:
recommendations of the Advisory Committee on Immu-
nization Practices (ACIP) and the American Academy of
Family Physicians (AAFP). MMWR 2006;55(No. RR-15).
• CDC. Influenza vaccination of health-care personnel:
recommendations of the Healthcare Infection Control
Practices Advisory Committee (HICPAC) and the Advi-
sory Committee on Immunization Practices (ACIP).
MMWR 2006;55(No. RR-2).
• CDC. Recommended immunization schedules for
persons aged 0–18 years—United States, 2007. MMWR
2007;55:Q1–4.
• CDC. Recommended adult immunization schedule—
United States, October 2006–September 2007. MMWR
2006;55:Q1–4.
• CDC. Guidelines for preventing health-care–associated
pneumonia, 2003: recommendations of CDC and the
Healthcare Infection Control Practices Advisory Com-
mittee. MMWR 2003;53(No. RR-3).
• CDC. Respiratory hygiene/cough etiquette in health-care
settings. Atlanta, GA: US Department of Health and
Human Services, CDC; 2003. Available at http://www.cdc.
gov/flu/professionals/infectioncontrol/resphygiene.htm.
• CDC. Prevention and control of vaccine-preventable dis-
eases in long-term care facilities. Atlanta, GA: US
Department of Health and Human Services, CDC; 2006.
Available at http://www.cdc.gov/flu/professionals/infection
control/longtermcare.htm.
• Sneller V-P, Izurieta H, Bridges C, et al. Prevention and
control of vaccine-preventable diseases in long-term care
facilities. Journal of the American Medical Directors
Association 2000;1(Suppl):S2–37.
• American College of Obstetricians and Gynecologists.
Influenza vaccination and treatment during pregnancy.
ACOG committee opinion no. 305. Obstet Gynecol
2004;104:1125–6.
• American Academy of Pediatrics. 2006 red book: report
of the Committee on Infectious Diseases. 27th ed. Elk
Grove Village, IL: American Academy of Pediatrics; 2006.
• Bodnar UR, Maloney SA, Fielding KL, et al. Preliminary
guidelines for the prevention and control of influenza-
like illness among passengers and crew members on cruise
ships. Atlanta, GA: US Department of Health and
Human Services, CDC; 1999. Available at http://www.
cdc.gov/travel/CDCguideflufnl.PDF.
• CDC. General recommendations for preventing influenza
A infection among travelers. Atlanta, GA: US Depart-
ment of Health and Human Services, CDC; 2003. Avail-
able at http://www2.ncid.cdc.gov/travel/yb/utils/
ybGet.asp?section=dis&obj=influenza.htm.
• US Public Health Service and the Infectious Diseases
Society of America. Guidelines for the prevention of
opportunistic infections among HIV-infected persons—
2002: recommendations of the U.S. Public Health Ser-
vice and the Infectious Diseases Society of America.
Washington, DC: US Department of Health and
Human Services; 2002. Available at http://aidsinfo.nih.
gov/contentfiles/OIpreventionGL.pdf.
• CDC. Infection control guidance for the prevention and
control of influenza in acute-care facilities. Atlanta, GA:
US Department of Health and Human Services, CDC;
2007. Available at http://www.cdc.gov/flu/professionals/
infectioncontrol/health-carefacilities.htm.
• Food and Drug Administration. FDA Pandemic influ-
enza preparedness strategic plan. Washington, DC: Food
and Drug Administration; 2007. Available at http://www.
fda.gov/oc/op/pandemic/strategicplan03_07.html.
• World Health Organization. Recommendations for
influenza vaccines. Geneva, Switzerland: World Health
Organization; 2007. Available at http://www.who.int/csr/dis-
ease/influenza/vaccinerecommendations/en/index.html.
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